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DOC2B ENHANCEMENT OF BETA CELL FUNCTION AND SURVIVAL 
 
Diabetes mellitus is a complex metabolic disease that currently affects an 
estimated 422 million people worldwide, with incidence rates rising annually. 
Type 1 diabetes (T1D) accounts for 5-10% of these cases. Its complications 
remain a major cause of global deaths. T1D is characterized by autoimmune 
destruction of β-cell mass. Efforts to preserve and protect β-cell mass in the 
preclinical stages of T1D are limited by few blood-borne biomarkers of β-cell 
destruction. In healthy β-cells, insulin secretion requires soluble n-
ethylmaleimide-sensitive factor-attachment protein receptor (SNARE) complexes 
and associated accessory regulatory proteins to promote the docking and fusion 
of insulin vesicles at the plasma membrane. Two target membrane (t)-SNARE 
proteins, Syntaxin 1/4 and SNAP25/23, and one vesicle-associated (v)-SNARE 
protein, VAMP2, constitute the SNARE core complex. SNARE complex assembly 
is also facilitated by the regulatory protein, Double C2-domain protein β (DOC2B). 
I hypothesized that DOC2B deficiency may underlie β-cell susceptibility to T1D 
damage; conversely , overexpression of DOC2B may protect β-cell mass. Indeed, 
with regard to DOC2B abundance, my studies show reduced levels of DOC2B in 
platelets and islets of prediabetic rodents and new-onset T1D humans. 
Remarkably, clinical islet transplantation in T1D humans restores platelet DOC2B 
levels, indicating a correlation  
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With regard to protection/functional effects, DOC2B deficiency enhances 
susceptibility to T1D in mice, while overexpression of DOC2B selectively in β-
cells protects mice from chemically induced T1D; this correlates with 
preservation of functional β-cell mass. Mechanistically, overexpression of 
DOC2B and the DOC2B peptide, C2AB, protects clonal β-cell against cytokine or 
thapsigargin-induced apoptosis and reduces ER stress; this is dependent on 
C2AB’s calcium binding capacity. C2AB is sufficient to enhance glucose 
stimulated insulin secretion (GSIS) and SNARE activation in clonal β-cells to the 
same extent as full-length DOC2B. In summary, these studies identify DOC2B as 
a potential biomarker and novel therapeutic target for prevention/management of 
T1D. 
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CHAPTER 1: INTRODUCTION 
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1.1. DIABETES AND CURRENT STANDARD OF CARE – WHAT’S NOT 
WORKING 
Diabetes mellitus is a complex disorder associated with increased risk of heart 
failure, stroke, blindness, neuropathy, and kidney disease, and is reaching 
epidemic proportions.  Out of the estimated 422 million people currently afflicted 
with diabetes worldwide, about 5% have type 1 diabetes (T1D), which results 
from autoimmune destruction of beta cell function and mass. The remaining 
~95% of diabetics have type 2 diabetes (T2D), a multi-tissue disease wherein 
peripheral insulin resistance is compounded by dysfunction and demise of beta 
cells.  
 
Treatment options for patients with T1D are limited. Currently, the mainstay T1D 
treatment is exogenous insulin replacement. Cutaneous insulin pumps and 
closed-loop insulin pumps can also be used for the automatic administration of 
insulin under basal and postprandial conditions. The danger in using exogenous 
insulin replacement, however, is that normal, glucose-dependent biphasic 
release of endogenous insulin is lost and life-threatening hypoglycemic episodes 
are often affiliated with this therapy. Moreover, the demise of beta cell mass 
persists. Other T1D therapies currently under investigation are mostly 
immunosuppressant drugs, such as rituximab, teplizumab, and Cyclosporin A. 
The problem in using this approach is that the long-term safety of these therapies 
remains unknown. Islet transplantation is currently offered as an investigational 
therapy and has proven to be promising in treating T1D [1]. However, islet 
 3 
 
transplantation procedures are limited by the number available donor islets, the 
need for immunosuppression, and the longevity of the grafted islets [2]. Thus, 
there is a need for novel T1D preventative therapies that can protect functional β-
cell mass against destruction.  
 
Unlike the limited monotherapy available for T1D, T2D by nature lends itself to 
various treatment approaches that aim to enhance insulin sensitivity, and others 
that aim to improve insulin secretion. Current T2D treatments range from diet and 
weight loss to various combinations of oral and injectable therapies (Table 1.1.). 
If diet and exercise are not sufficient to meet the accepted Hemoglobin A1c 
(HbA1c) threshold (typically < 7.5%), pharmacotherapy is initiated. The first line 
therapy, metformin, belongs to the family of biguanidine drugs and is thought to 
reduce blood glucose levels primarily by suppressing gluconeogenesis in the 
liver via activation of AMPK. However, the precise mechanism of action of 
metformin is poorly understood. Importantly, metformin is contraindicated in 
individuals with renal, liver, or cardiorespiratory failure, and is known to cause 
gastrointestinal side effects, which significantly limits its use. For those patients 
who cannot take metformin, or have no significant improvement in HbA1c, the 
second line therapy recommended for T2D patients is combination therapy of 
insulin and a sulfonylurea. Sulfonylureas work at the level of the beta cell to 
enhance insulin secretion via binding to the ATP-dependent potassium channel 
(KATP). While sulfonylurea use is rapidly effective and has been shown to reduce 
microvascular complications [3], the risk of hypoglycemia and accompanying 
 4 
 
weight gain associated with sulfonylurea therapy are major treatment-limiting 
factors.   
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Table 1.1. Current T2D treatments   
Treatment Target  Mechanism  Advantages Disadvantages 
Tier 1: First-Second Line Therapies 
Biguanide  Liver ↑ hepatic insulin 
sensitivity; 
↓ 
gluconeogenesis 
and lipogenesis, 
via activating 
hepatic AMPK 
↓ macrovascular 
events and 
mortality 
(UKPDS);   
Weight neutral;  
No 
hypoglycemia 
GI side effects;  
Contraindicated in 
patients with kidney, 
liver, 
cardiorespiratory 
insufficiency, 
alcoholism or older 
age. 
Insulin Sk.Muscle 
Adipose 
 
Liver 
↑ glucose uptake 
in muscle, fat; 
↓ hepatic glucose 
output  
Rapidly 
effective; 
Improved lipid 
profile 
Hypoglycemia; 
Daily injections; 
Constant monitoring. 
Sulfonylurea 
 
Pancreatic 
beta cell 
↑ insulin 
secretion via 
binding to ATP-
dependent K+ 
channel 
↓ microvascular 
complications 
(UKPDS); 
Rapidly effective 
Severe 
hypoglycemia; 
GI issues, weight 
gain;  
CV safety issues; 
Hasten beta cell 
death. 
Tier 2: Lesser-Validated Therapies 
Thiazolidine
dione 
[TZDs] 
 
Liver 
Adipose 
↑ expression of 
genes that 
promote lipid 
storage and 
enhance hepatic 
insulin sensitivity 
↓ loss of beta 
cell function;  
↑ insulin 
sensitivity  
↑ MI risk; 
Weight gain; 
Fluid retention; 
↑ LDL, cholesterol; 
↑ Bone fracture risk 
in women. 
GLP-1 
agonist 
 
Pancreatic 
beta cell 
↑ insulin 
secretion via 
binding to GLP-1 
receptor 
Weight loss; 
↓ hypoglycemic 
episodes 
↑ GI side effects; 
Requires injection; 
Fail if patients are 
insulinopenic. 
Other Therapies 
DPP-4 
inhibitor  
 
Pancreatic 
beta cell 
Inhibit cleavage 
of endogenous 
GLP-1 
Weight neutral Long-term safety ?; 
Risk of heart failure 
SGLT2 
inhibitor 
 
Renal 
proximal 
tubule 
Inhibits sodium-
glucose 
cotransporters,  
Weight loss;  
↓ systolic blood 
pressure 
urinary tract 
infections; 
Long-term safety ? 
Alpha-
glucosidase 
inhibitor 
 
Small 
intestine 
Delays 
carbohydrate 
digestion 
Weight neutral; 
No 
hypoglycemia if 
taken alone 
↑ GI side effects. 
Meglitinide 
 
Pancreatic 
beta cell 
↑ insulin 
secretion via 
binding to KATP 
channel 
Rapidly effective Hypoglycemia; 
Weight gain; 
Frequent dosing. 
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If sulfonylurea/insulin therapy is ineffective or causes side effects, the 
recommended Tier 2 therapy is the use of thiazolidinediones (TZDs). Tier 2 
classification denotes therapies that are lesser-validated than Tier 1 therapies. 
TZDs lower blood glucose levels by increasing the expression of genes that 
promote lipid storage and enhance hepatic insulin sensitivity (Table 1.1.). 
However, the FDA has recently restricted TZDs due to affiliated severe risk of 
myocardial infarction, weight gain, and fractures. In lieu of prescribing TZDs, 
physicians may prescribe a glucagon-like receptor (GLP-1) agonist, a class of 
drugs that mimic the effects of the incretin, GLP-1, which causes increased 
insulin secretion, decreased glucagon release, increased satiety and reduced 
gastric motility. Although GLP-1 agonists have been shown to promote weight 
loss and have relatively lower risk of hypoglycemia, the frequent and often 
severe gastrointestinal side effects associated with GLP-1 agonists limit their use 
as well. Alarmingly, new evidence shows long term use of the GLP-1 agonist, 
Liraglutide, compromises human beta cell function in vivo [4]. Other therapies 
include dipeptydyl peptidase-4 (DPP-4 inhibitors), sodium-glucose cotransporter-
2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, and meglitinides; these act by 
increasing endogenous GLP-1 levels, inhibiting glucose reabsorption from the 
proximal tubule of the kidney, delaying carbohydrate digestion, and increasing 
insulin secretion, respectively. In addition, DPP-4 inhibitors can increase heart 
failure risk, alpha-glucosidase inhibitors cause gastrointestinal side effects, and 
meglitinides carry the risk of hypoglycemic episodes.  
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Taken together, it is clear that currently available therapy options for T2D are 
limited in terms of long-term safety, of achieving optimal glucose-dependent 
insulin secretion or promoting/protecting functional beta cell mass. Furthermore, 
none of these therapies directly promote skeletal muscle-mediated insulin 
sensitivity and action (i.e. glucose uptake), which accounts for ~80% of all excess 
glucose disposal by peripheral tissues [5, 6]. With 30-40% of the U.S. population 
predicted to be at risk for diabetes [7], this creates an urgent need for novel 
therapies that can dually protect functional beta cell mass and peripheral insulin 
sensitivity. 
 
A review of the literature spanning the past 25 years reveals dually active factors 
that are required in both beta cell function and peripheral insulin action – SNARE 
proteins. Indeed, in the late 1990’s, Nagamatsu and colleagues [8] demonstrated 
that diabetic GK rat islets were deficient in two t-SNARE proteins, Syntaxin 1A 
(STX1A) and SNAP25, and that replenishment of these factors resolved islet 
dysfunction. More recently, we demonstrated the capacity to restore normal 
function to dysfunctional T2D human islets by replenishing Syntaxin 4 (STX4), 
previously considered to be an inactive and redundant t-SNARE isoform in the -
cell [9]. Thus, my dissertation studies sought to explore emerging evidences that 
suggest there are deficiencies/defects in exocytosis proteins in diabetic rodents 
and humans, and to interrogate the consequences of overexpressing certain 
exocytosis factors in the context of maintaining glucose homeostasis. In doing so, 
I have assessed clues from other diseases, such as neurodegenerative disorders 
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and cancer, for which there is accumulating data on the benefits of replenishing 
deficient exocytosis proteins. 
 
1.2. SNARE EXOCYTOSIS MACHINERY: THE “NUTS AND BOLTS” 
Exocytotic trafficking of proteins and lipids from the cytosol to the cell exterior 
constitutes one of the most important processes in the cell. Most eukaryotic cells 
achieve this via packaging of protein or lipid cargo in membrane-bound vesicles, 
which originate from the trans-Golgi network or recycling endosomes and are 
subsequently transported via cytoskeletal remodeling to the plasma membrane. 
Once at the membrane, vesicle docking, priming, and fusion depends on the 
high-affinity interaction of a complex of highly conserved proteins called SNAREs 
(soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors). 
This fundamental mechanism of regulated SNARE complex assembly is 
conserved in many different cells types, including neurons, exocrine, 
hematopoetic, and endocrine cells.  
1.2.1. The SNARE core complex 
The SNARE complex consists of two target membrane (t)-SNARE proteins, 
Syntaxin (STX) and SNAP23 (or SNAP25), and one vesicle associated (v-
SNARE) protein, VAMP [10-15]. STX proteins are ~35 kDa containing a carboxy-
terminal transmembrane domain spanning the plasma membrane and an N-
terminus oriented toward the cytoplasm [16]. The other t-SNARE type, SNAP-
23/25 (23 or 25 kDa in size), is associated with the plasma membrane via 
palmitoylation of four cysteine residues in the central region of the protein [17]. 
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The v-SNARE, VAMP, is a 18-20 kDa protein with a vesicle membrane-spanning 
carboxyl terminus and an N-terminus oriented away from the vesicle, toward the 
cytoplasm [15]. Ultrastructural evidence of the SNARE complex shows that one 
v-SNARE binds with two cognate t-SNARE proteins in a heterotrimeric 1:1:1 ratio 
[12, 14]. This SNARE core complex is extremely stable and is sufficient to 
withstand the energy barrier required to fuse the vesicle to the membrane [18]. 
Once fused, the SNARE complex is described as being in ‘cis’ configuration, as 
opposed to when the vesicle is previously docked or tethered and in ‘trans’ 
configuration (when the lipid bilayer of the vesicle is distinct from the plasma 
membrane, not yet having merged). The SNARE core complex is notoriously 
SDS-resistant, requiring boiling in SDS-containing buffer to dissociate into free 
monomers. Following vesicle fusion, the cis- complex SNARE proteins are bound 
by alpha-SNAP and NSF (N-ethylmaleimide sensitive factor) proteins to catalyze 
SNARE complex dissociation, allowing endocytosis of the v-SNARE and 
recycling of the individual t-SNAREs back to their respective plasma membrane 
compartments [12]. 
1.2.2. Regulation of the core complex -- SNARE accessory factors 
SNARE-mediated vesicle fusion is tightly regulated by accessory binding proteins, 
such as “SM” (Sec1/Munc18), Munc13, and DOC2 (double C2-domain containing 
proteins). Munc18 proteins, also called “syntaxin binding proteins (STXBP)”, are 
~66-68 kDa in size, are soluble, and do not contain a transmembrane domain 
[19]. These proteins are localized to the cytosol, and to the plasma membrane 
through direct interaction with their cognate Syntaxin partners [20, 21]. It is 
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proposed that upon stimulation, Munc18 proteins assist Syntaxin’s 
conformational change to its accessible, “open” or “active” conformation for its 
subsequent engagement as part of the SNARE core complex (i.e. VAMP, 
SNAP23/25, STX), and docking and fusion of vesicles [22, 23].  
 
In addition to SM proteins, the calcium- and phosphoinositide binding protein 
isoform DOC2B has been shown to be essential for SNARE core complex 
assembly to occur in islet beta cells and muscle/fat cells [24, 25]. DOC2B is a 
ubiquitously expressed 46-50 kDa protein. In islet beta cells, DOC2B binds to the 
SNARE regulatory proteins Munc18-1 and Munc18c, via its C2A and C2B 
domains, respectively [26-28]. Other calcium-sensing C2-domain-containing 
proteins, including Munc13 and synaptotagmin, are implicated in accelerating 
SNARE complex formation and insulin release from beta cells via fostering 
STX1-based actions [29-32]. In skeletal muscle cells, DOC2B facilitates STX4-
based actions [33]. Since many of these regulatory factors are implicated in T2D, 
I will discuss in detail their tissue-specific and conserved mechanisms required 
for insulin secretion and peripheral insulin action, in the following section. 
 
1.3. TISSUE-SPECIFIC AND CONSERVED SNARE PROTEINS IN DIABETES-
RELATED TISSUES  
Amongst the diabetes-related tissues (pancreatic beta cells, skeletal muscle cells, 
fat cells), there are exocytosis factors that are cell-type specific, and other factors 
that are conserved but that exhibit distinct mechanisms suited to the function of 
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that tissue in maintaining glucose homeostasis. As depicted in Figure 1.1., the 
set of SNARE core complex proteins required by beta cells, fat cells and muscle 
cells consists of STX4, SNAP23, and VAMP2. Islet beta cells, being 
neuroendocrine-derived, also express and utilize neuronal-specific isoforms of 
SNARE proteins, namely STX1A, SNAP25, DOC2A and Munc18-1. Hence, beta 
cells have some overlapping and functional redundancy in SNARE isoform 
usages. By contrast, skeletal muscle and fat cells have little to no redundancy, 
with only one t-SNARE of each type expressed (STX4 and SNAP23). Additional 
t- and v-SNAREs shown in Figure 1.1. are reportedly expressed and used in 
some cases but are not necessarily required for normal function (e.g. VAMP3). 
The following sections will explore the detailed mechanisms underlying beta cell 
insulin secretion and skeletal muscle glucose uptake. Of note, while the focus of 
this review is to highlight pre-diabetes and T2D through the lens of SNAREs 
levels, SNARE defects are one of a number of other defects (e.g. signaling) that 
contribute to T2D. 
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Figure 1.1. SNARE and SNARE accessory protein isoforms utilized by islet 
beta cells and skeletal muscle cells for vesicle exocytosis: a common 
subset of factors. Factors listed in the beta cell (left circle, blue) are known to 
facilitate glucose-stimulated insulin secretion, and those listed in the skeletal 
muscle cell (right circle, red) are required for insulin-stimulated glucose uptake. 
Those isoforms utilized by both beta cells and muscle cells are shown in the 
center of overlap.  
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1.4. EXOCYTOSIS IN THE BETA CELL: BIPHASIC GLUCOSE STIMULATED 
INSULIN SECRETION  
Interestingly, although the majority of the SNARE isoforms were identified in the 
early 1990’s [34], only the neuronal cluster of STX1A, SNAP25 and VAMP2 were 
initially studied for functionality in insulin release mechanisms. SNAP23 was 
found capable of substituting for SNAP25 in insulin secretion [35] shortly 
thereafter, but it was another decade before the functional requirements for other 
Syntaxin and SM isoforms such as Syntaxin 4 (STX4), Munc18b and Munc18c, 
were examined in the process of insulin release [36-38]. The beta cell is now 
known to express and use all four plasma membrane localized STX isoforms, 
STX1-4. At the plasma membrane, isoforms STX1-3 can bind to Munc18-1 (also 
called Munc18a) and Munc18-2 (Munc18b) [19, 39, 40], whereas only STX4 can 
bind to Munc18c [41, 42]. The following section discusses the ornate complexity 
of how these SNARE proteins are utilized that contributes to the biphasic pattern 
of insulin release. 
1.4.1. Biphasic secretion and affiliated SNARE complexes in the beta 
cell 
Insulin granule exocytosis in the pancreatic beta cell is elicited in two discrete 
phases in response to a nutrient stimulus, commonly referred to as glucose-
stimulated insulin secretion (GSIS). GSIS is evoked by sensing of the beta cell to 
a stimulatory level of extracellular glucose (16.7 mM most commonly used 
experimentally). This glucose enters the beta cell by passing through the 
constitutively-plasma membrane localized glucose transporter, GLUT2 (rodent) 
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or GLUT1 (human) [43]. Once inside the beta cell, glucose is metabolized to yield 
an increased ratio of cellular ATP:ADP. Increased ATP induces closure of the 
KATP channels, causing membrane depolarization and opening of voltage-
dependent calcium channels, increasing intracellular calcium ([Ca2+]i) levels. 
Elevated [Ca2+]i triggers the SNARE and regulatory proteins to facilitate priming 
and fusion of insulin-filled granules with the plasma membrane to prompt release 
of the insulin cargo from the cell. This chain of events constitutes the first-phase 
of GSIS (Figure 1.2.), occurring within 5-10 minutes of glucose stimulation, and 
uses STX1A- or STX4-based SNARE core complexes involving SNAP25 or 
SNAP23, and VAMP2 [35, 38, 44-46]. Second-phase insulin release, which is 
characterized by the mobilization of insulin granules from intracellular storage 
pools out to the plasma membrane, occurs beyond 10 minutes of glucose 
stimulation. Second-phase GSIS utilizes STX4, SNAP25 or SNAP23, and 
VAMP2 [38, 44, 47] (Figure 1.2.). Recent reporting has also shown that STX1A 
may be involved in second-phase GSIS as well [48]. Other Syntaxin isoforms, 
(e.g. STX2 and STX3) have also been shown to participate in beta cell 
exocytosis events, although are affiliated with more rare forms of exocytosis [49-
51]. Another v-SNARE protein, VAMP8, also functions in insulin secretion but is 
required selectively for glucagon-like peptide (GLP-1) enhanced insulin release 
[52]. VAMP3 is also expressed in the -cell, but knockout mouse models 
exhibited no secretion defects, suggesting that this isoform may be redundant 
[53]. 
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Figure 1.2. Differential requirement of SNARE and SNARE accessory 
protein isoforms during each phase of glucose stimulated insulin secretion 
from islet beta cells. While the first-phase of insulin release uses both STX1- 
and STX4-based complexes, the second phase of insulin release relies upon 
STX4-based SNARE complexes. Accessory factors shown to be affiliated with 
these complexes are also grouped with the corresponding t- and v-SNARE core 
complexes. Note: SNAP25/23 denotes that SNAP25 and SNAP23 both suffice in 
the affiliated complex. 
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 1.4.2. Regulation of Insulin Secretion -- SNARE accessory proteins 
While it is generally agreed that the Munc18 proteins facilitate the SNARE 
complex assembly process, the detailed protein-protein interaction changes in 
response to glucose stimulation are not agreed upon. For example, both 
Munc18-1 and Munc18c have been demonstrated to undergo phosphorylation 
and subsequent dissociation from their cognate STX partner [54-56]. However, 
other reports suggest that the Munc18 proteins remain bound or will reposition to 
become part of the final SNARE complex [57, 58]. In general, studies favoring 
the dissociation model stem from cell or tissue studies, whilst the other model 
stems from in vitro assays. Interestingly, Munc18c is only required for second-
phase insulin secretion, whereas STX4 and DOC2B are required for both phases 
[24, 36, 38] (Figure 1.2.). Munc18-1 regulates first-phase secretion, and while 
initially this was presumed to occur via STX1A binding changes, it was later 
discovered that Munc18-1 overexpression enhances STX4 activation [59]; this 
has been since proposed as an explanation for why STX4 functions in first-phase 
insulin release. 
 
Akin to the controversy described above regarding the molecular binding 
mechanisms of Munc18 proteins, the details regarding DOC2B’s mechanism(s) 
of action are controversial. For example, Figure 1.3.A depicts DOC2B binding to 
Munc18-1 and Munc18c directly, via DOC2B’s C2A and C2B domains, 
respectively, scaffolding both Munc18 isoforms concurrently in a heterotrimeric 
complex [26]. Alternatively, it has been suggested that DOC2B binds to STX4 
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rather than Munc18 proteins, involving a calcium-dependent mechanism [60] 
(Figure 1.3.B). The key difference between proposed mechanisms is the direct or 
indirect nature of DOC2B binding to STX4 to evoke its activation. While the 
details of the direct binding model (Figure 1.3.B) are still evolving, the Munc18-
binding model (Figure 1.3.A) purports that glucose stimulation triggers rapid 
Munc18c phosphorylation, switching its affinity for binding to DOC2B and away 
from STX4, which permits STX4 opening for its engagement in SNARE core 
complexes [56]. As described below, some of these mechanistic concepts are 
also proposed in GLUT4-dependent glucose uptake in peripheral tissues.  
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Figure 1.3. Proposed mechanisms underlying the benefits of DOC2B 
overexpression. Overexpression of DOC2B has shown positive effects on 
whole body glucose homeostasis. The mechanism by which DOC2B 
overexpression exerts is positive effects in beta/muscle cells is still yet to be 
elucidated. (A) DOC2B proposed to function as a scaffold for Munc18-1 and 
Munc18c binding and subsequent activation of STX4. (B) DOC2B proposed to 
directly bind to STX4, allowing for STX4 activation and promotion of SNARE 
formation. (C) DOC2B proposed to bind the light chain (Tctex-1) of motor protein, 
Dynein, which functions along microtubules. DOC2B may act direct/indirectly on 
actin remodeling, subsequently allowing for translocation of vesicles to the 
plasma membrane. 
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1.5. EXOCYTOSIS OF GLUT4 VESICLES AND GLUCOSE UPTAKE IN 
SKELETAL MUSCLE AND FAT CELLS 
Following a meal, glucose uptake into peripheral skeletal muscle accounts for 
~80% of whole body glucose clearance, whereas fat cells account for the 
remaining 20% via intracellular processes that promote trafficking of the vesicle 
containing the insulin-responsive glucose transporter, GLUT4 [61-65]. This 
process begins with insulin binding to the insulin receptor (IR) to induce its 
tyrosine autophosphorylation, which in turn activates the canonical PI3K→AKT 
signaling pathway, triggering the intracellularly localized GLUT4-containing 
vesicles to translocate to the sarcolemmal and T-tubule membranes, where the 
vesicles are docked and fused via SNARE proteins.  
 
In the late 1990’s numerous groups independently deduced that the t-SNARE 
isoforms STX4 and SNAP23, and v-SNARE VAMP2, comprised the machinery 
necessary and sufficient for GLUT4 vesicle docking/fusion [66-70]. This 
mechanism was later expanded to include a pivotal regulatory step by which the 
SNARE complex assembled: the insulin-activated IR directly phosphorylates 
Munc18c to trigger the activation of STX4, fostering SNARE complex formation 
[71, 72]. Since Munc18c phosphorylation occurs independently of PI3K, these 
results gave rise to the current model, wherein insulin elicits a coordinated 
response through activation of IR to evoke t-SNARE assembly in sync with PI3K-
mediated vesicle mobilization to the plasma membrane, culminating in coordinate 
SNARE core complex formation and GLUT4 vesicle fusion. Given the ubiquitous 
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expression of this grouping of SNARE and SNARE accessory factors, this also 
provides a testable model for other exocytosis events initiating from pivotal 
extracellular signals. 
1.5.1. Regulation of GLUT4 Translocation/Glucose uptake – 
controversy surrounding SNARE accessory proteins 
While all groups agree fully that DOC2B plays a positive role in regulating insulin-
stimulated GLUT4 vesicle exocytosis and SNARE complex formation, DOC2B’s 
mechanism(s) of action in peripheral tissues, like those described in the beta cell, 
remain controversial, depending upon the experimental system used to derive 
the mechanism. For example, studies of primary mouse skeletal muscle or 
GLUT4myc-L6 myoblasts show that insulin stimulation increased DOC2B binding 
to phosphorylated Munc18c, coordinate with increased STX4 activation and 
SNARE complex formation [24, 33]. Consistent with this, DOC2B knockout (-/-) 
mouse skeletal muscle harbors abundant Munc18c-STX4 complexes and 
reduced SNARE complex formation [24]. In contrast, studies using 3T3L1 
adipocytes or in vitro mixing assays using recombinant DOC2B report a direct 
STX4-DOC2B binding interaction [73, 74]; this interaction is not observed in 
primary tissues or L6 muscle cells [24]. Although this has yet to be 
experimentally reconciled, differences that might underlie these distinct 
mechanisms could be that the in vitro and 3T3L1 adipocyte studies assessed 
DOC2B association with STX4 using co-immunopreciptations from cell lysates, a 
method that cannot distinguish direct from indirect binding interactions [73, 75]. In 
vitro studies also exclude additional DOC2B binding factors (such as microtubule 
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and/or actin cytoskeletal factors) that might otherwise influence how DOC2B 
associates with STX4. Indeed, DOC2B has been shown to interact with 
microtubule-associated Tctex-1 type proteins [75, 76]. Additionally, STX4 
interacts with F-actin via the protein, Gelsolin [77]; this STX4-F-actin interaction 
may very well coordinate with microtubule-dependent trafficking of insulin, as 
insulin granules are known to require microtubule tracks for transport to the 
plasma membrane [78]. Hence, microtubule factors might bridge the DOC2B-
STX4 interaction (as modeled in Figure 1.3.C). DOC2B also harbors an N-
terminal Munc13 interacting domain (referred to as the MID domain), yet no 
Munc13 partners for DOC2B are yet identified in fat or skeletal muscle cells. 
Bridging factors remain relatively unexplored as potential targets for improving 
peripheral insulin sensitivity. 
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1.6. DEFICIENT, DEFECTIVE AND MIS-LOCALIZED EXOCYTOSIS FACTORS 
IN T2D TISSUES 
Following the discovery of important SNARE isoforms involved in insulin 
secretion and glucose uptake, several reports published data correlating 
deficiencies in SNARE and regulatory proteins to T2D and obesity in human 
subjects (as referenced in Table 1.2.). Several recent reports link polymorphisms 
in STX1A to impaired glucose metabolism in obese human subjects, and to the 
age of onset and insulin requirement in T2D individuals [79, 80]. Another report 
links decreased STX4 gene expression with T2D and psoriasis [81], and 
suggested that STX4 be considered a biomarker for T2D development in 
psoriasis cases. STX4, amongst other SNARE proteins such as STX1A, SNAP25 
and VAMP2, have all been shown to be deficient in T2D human islets (Table 
1.2.). Notably, the regulatory factors of these SNARE proteins, such as multiple 
Munc18 isoforms, DOC2B, Munc13-1, multiple synaptotagmin isoforms, and 
synaptophysin, are also deficient [8, 9, 31, 82-86]. Interestingly, SNAP23 was 
noted to be deficient at the site of exocytosis (the plasma membrane), but overall 
quantities were either unchanged or even increased [9, 87]. Modeling this in 
spontaneous rodent models of pre-diabetes and T2D, such as the obese and 
diabetic Zucker rats and the non-obese diabetic GK rat, revealed that many of 
these same exocytosis factor deficits are conserved (Table 1.2.). Although recent 
studies point to significant differences between human and mouse islets in terms 
of islet architecture and islet cell function, deficiencies in SNARE proteins under 
conditions of obesity and T2D are uniformly similar. Many SNARE deficiencies 
 23 
 
have been studied using gene-targeted ablation knockout mouse models, 
resulting in dysregulated metabolic phenotypes. This raises the question as to 
whether deficiencies of SNARE/regulatory proteins are a cause or a 
consequence of diabetes. The prevailing hypothesis is that deficiencies of 
SNAREs are likely a consequence of diabetes. However, STX1 gene mutations 
and polymorphisms have been linked with T2D, and SNAREs are noted as being 
targets of miRNA [88, 89] and lncRNAs [90, 91], suggesting that genetic and/or 
epigenetic links will need to be explored to fully address this question. 
Furthermore, whether exocytosis protein deficiency underlies -cell dysfunction 
in T1D remains under explored. This is a particularly important point of interest, 
as the preclinical phase of T1D is marked by declining β-cell function [92, 93], 
and there exists a critical need for the ability to assess early loss of functional β-
cell mass in predicting T1D onset. 
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  Protein 
 
Tissue Protein 
Levels in T2D 
Humans 
Protein Levels 
in T2D Rodents 
References 
DOC2B Islets Decreased ND [85] 
Munc13-1 Islets Decreased  Decreased in 
diabetic GK and 
obese Zucker 
fa/fa rats  
[31, 82] 
Munc18-1 Islets Decreased ND [9, 82] 
Munc18c Islets; 
Sk. 
Muscle; 
Adipose 
Decreased  
Decreased  
Decreased 
Decreased  
Decreased in 
diabetic GK rats   
[8, 82-84, 
94] 
SNAP23 Sk. 
Muscle 
Decreased at 
site of 
exocytosis 
(PM)  
ND [87] 
SNAP25 Islets Decreased  Decreased in 
diabetic GK rats  
[8, 82, 94] 
STX1A Islets Decreased 
SNP (D68D, T 
to C) 
correlates to 
age at onset 
and insulin 
requirement in 
T2D 
Decreased in 
hyperglycemic 
GK rats 
[8, 9, 80, 
82, 86] 
STX4 Islets, 
Sk. 
Muscle 
Decreased in 
both tissues 
 
ND [9, 84] 
Synaptophysin Islets Decreased  ND [82] 
Synaptotagmin 
4, 7, 11 
Islets Decreased  ND [86] 
VAMP2 Islets Decreased  Decreased in 
diabetic GK rats    
[82, 94] 
Table 1.2. Exocytosis protein expression in Type 2 diabetic humans and 
rodents. Note: presented in alphabetical order of protein name. ND, not 
determined. Sk. Muscle, skeletal muscle; GK, Goto-Kakizaki.  
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1.7. CAN DEFICIENT/DEFECTIVE EXOCYTOSIS FACTORS BE 
REPLENISHED TO REMEDIATE DISEASE? CLUES FROM 
NEURODEGENERATIVE DISORDERS  
One of the earliest reports linking defects in exocytosis proteins to human 
disease involved senile plaques of Alzheimer subjects, which were found to be 
deficient in exocytosis proteins - namely STX1A, synapsin, snaptophysin and 
synaptotagmin [95]. Akin to findings in islets described above, deficiencies in 
SNAP25 and STX1A were found in patients with Creutzfeldt-Jakob disease [96] 
(Figure 1.4.). Decreased abundances or functions in exocytosis proteins were 
also reported in subjects with Huntington’s disease, Schizophrenia and Attention-
Deficit/Hyperactivity Disorder [97-101]. In each disease, treatments involved 
restoration of SNARE proteins (Figure 1.4.). Related to this, STX4 replenishment 
to human T2D islet cells restored glucose-stimulated insulin secretory function 
equivalent to that of non-diabetic age-matched human islets [9], providing proof 
of concept for this as a restorative approach.  
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Figure 1.4. Exocytosis proteins implicated in human neurological and 
metabolic diseases. SNARE protein abundances (STX4, STX1A, SNAP25, and 
VAMP2) are decreased and genetic polymorphisms are implicated in a variety of 
neurodegenerative, autoimmune, and metabolic diseases. Therapies are 
proposed based on current studies that aim to replenish/preserve abundance of 
exocytosis proteins. 
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1.8. ARE EXOCYTOSIS PROTEINS IMPLICATED IN CELL SURVIVAL AND 
PROLIFERATION? CLUES FROM CANCER  
1.8.1. STX4 and DOC2B as Targets to Combat Cancer?  
Recent investigations have suggested that STX4 and DOC2B may act as tumor 
suppressors. For example, downregulation of STX4 was recently shown to be 
associated with cancer cell proliferation, as STX4 is required for acid 
sphingomylinase translocation, a vesicle trafficking event needed for normal 
apoptotic mechanisms [102]. Similarly, DOC2B is required to regulate pro-
apoptotic mechanisms in human cervical cancer cells, combating their 
proliferation; DOC2B transcription was found to be downregulated in several 
human cancer cell lines due to hypermethylation of the DOC2B promoter [103]. 
DOC2B replenishment in cervical cancer cells led to increased actin cytoskeleton 
remodeling, and inhibition of AKT and ERK hyper-phosphorylations, yielding 
attenuation of cell migration to decrease cancer cell growth [103]. Importantly, no 
increases in common mitogenic pathway proteins such as MAPK, ERK, or mTOR 
mitogenic pathways were reported with overexpression of STX4 or DOC2B. This 
suggests that efforts to overexpress STX4 or DOC2B as a means to treat -cell 
and/or skeletal muscle dysfunction may be safe from tumor/cancer inducing side 
effects. This is a necessary consideration since efforts to increase -cell mass 
are currently being scrutinized with concerns about inducing cancer. 
1.8.2. STX4 and DOC2B – Potential Roles in Proliferation  
Despite studies suggesting that STX4 and DOC2B have tumor suppressor 
capabilities, other studies have implicated STX4 and DOC2B in playing roles in 
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proliferating cells during early embryogenesis. For example, STX4 homozygous 
(-/-) null mice died during early embryogenesis [69], and this was later linked to 
STX4’s vital role in facilitating GLUT8 exocytosis to support glucose influx for the 
growing blastocysts [104]. In neurons, DOC2B expression occurs long before 
neurotransmitter release is functional, and this early expression pattern of 
DOC2B correlates with that of genes involved in neuronal proliferation and 
differentiation, such as the neuroepithelial stem cell marker, nestin [105]. 
Furthermore, studies have shown that DOC2B has a critical role in synaptic 
vesicle trafficking as early as embryonic day 18 (E18), as neurons from DOC2B 
deficient (-/-) knockout mice of this age exhibited impaired spontaneous release 
frequency [106]. This points to a putative role for DOC2B in the delivery of 
membrane proteins to the surface of proliferating neurons and/or to the tip of 
outgrowing axons. Whether overexpression of STX4 or DOC2B could be 
harnessed as a means to protect/promote beta cell proliferation will be an 
important area of future investigation. 
1.9. EXOCYTOSIS PROTEIN REPLENISHMENT AND GLUCOSE 
HOMEOSTASIS: ISOFORM SPECIFICITY MATTERS  
The first demonstration that restoration of t-SNAREs to normal levels could 
recover insulin secretion in diabetic GK rat islets provided proof of concept for 
SNARE replenishment as an approach for restoring islet function [8]. The 
increasing evidences of exocytosis protein deficiencies in islets of obese and 
diabetic humans and rodents spurred the generation of several transgenic rodent 
models designed to test the effect of increased abundance of specific SNARE 
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isoforms on the regulation of islet function and glucose homeostasis in vivo 
(Table 1.3.).  
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 Genotype 
 
Alteration Metabolic Phenotype References 
STX1A Increased STX1A 
in pancreatic 
beta cells 
Fasting hyperglycemia, 
reduced insulin secretion, 
insulin intolerance in male 
mice.  
[107] 
STX4 Increased STX4 
in skeletal 
muscle, fat, and 
pancreas 
Enhanced insulin sensitivity, 
GLUT4 translocation and 
skeletal muscle glucose 
uptake;  
Enhanced insulin secretion 
from islets; 
Increased healthspan, 
lifespan;  
Protected from age- and 
HFD-induced metabolic 
dysfunction.  
[9, 38, 108, 
109] 
VAMP2 Increased 
VAMP2 in 
neurons  
ND [110] 
Munc18-1 Increased 
Munc18-1 in 
neurons  
ND [111] 
Munc18c Increased 
Munc18c in fat, 
skeletal muscle 
and pancreas 
Insulin resistant, glucose 
intolerant with impaired 
skeletal muscle glucose 
uptake; impaired insulin 
secretion from islets.  
[112] 
DOC2B  Increased 
DOC2B in 
skeletal muscle, 
fat, and pancreas 
Enhanced insulin sensitivity, 
GLUT4 translocation and 
skeletal muscle glucose 
uptake;  
Enhanced insulin secretion 
from islets.  
[33] 
Table 1.3. Transgenic mouse models of exocytosis protein overexpression 
ND, not determined. 
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1.9.1. STX1A and Munc18c - unexpectedly ineffective  
Despite a deficiency of STX1A and Munc18c in diabetic human and rodent islets 
(Table 1.2.), over-expression of either STX1A or Munc18c in transgenic mice did 
not improve glucose tolerance as expected – instead, both models exhibited 
profound glucose intolerance [107, 112]. Beta cell-specific STX1A 
overexpressing mice harbored beta cells that were functionally defective, with 
reduced depolarization-evoked membrane capacitance and reduced currents 
through the Ca2+ channels [107]. Years later, STX1A was shown to bind to the 
SUR1 regulatory subunit of islet beta cell KATP channels when overexpressed, 
inhibiting the activity of the channels and causing secretion defects [113]. 
Munc18c overexpression revealed a similar limitation – Munc18c transgenic mice, 
overexpressing Munc18c by as little as 2-3 fold in pancreas, skeletal muscle and 
adipose tissues, harbored dysfunctional islets as well as insulin-resistant skeletal 
muscle [112]. In both cell types, the additional Munc18c bound and sequestered 
endogenous STX4, reducing the formation of STX4-based SNARE complexes. 
These inhibitory actions leave STX1A and Munc18c with too narrow a window of 
efficacy for remediating islet function or skeletal muscle functions. 
1.9.2. STX4 – an expandable hub for excitosomes?  
In contrast to mice overexpressing STX1A, mice overexpressing STX4 
(simultaneously in pancreatic islets, skeletal muscle, and adipocytes) exhibited 
enhanced glucose homeostasis, resulting from increased skeletal muscle insulin 
sensitivity and islet function [108] (Table 1.3.). This is an important distinction 
between the two STX isoforms, and points to important structure-function 
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differences between these t-SNARE proteins. Amino acid alignment of STX1A 
and STX4 shows only 45% sequence similarity, supporting the concept that 
STX4 partners with significantly different factors. One such factor is filamentous 
actin (F-actin). Through its unique N-terminal alpha-spectrin like domain, STX4 is 
the only SNARE protein capable of direct F-actin binding [77, 114-116]. Moreover, 
in beta cells STX4 can associate with the actin binding and severing protein 
Gelsolin, and in 3T3-L1 adipocytes with the F-actin crosslinking protein alpha-
fodrin [77, 117]. Both STX4-cytoskeletal protein associations are affiliated with 
positive effects upon vesicle exocytosis in beta cells and fat cells. Although 
insulin granule exocytosis from beta cells requires actin depolymerization [118-
120], whilst GLUT4 vesicle exocytosis requires F-actin polymerization [121-123], 
both are considered F-actin remodeling events that may coordinate the timing of 
STX4 activation with the arrival of incoming granules/vesicles. If true, STX4’s 
interaction with the actin cytoskeleton may constitute an “excitosome”, a localized 
site at the plasma membrane with concentrated SNARE complex proteins and 
accessory proteins that promote granule docking to the membrane [124, 125]. 
Overexpression of STX4 may provide the basis for more excitosomes, i.e. more 
docking sites for exocytosis in skeletal muscle and beta cells.  
 
The translational implication of targeting exocytosis proteins for diabetes 
remediation has been effectively demonstrated with STX4 in human pancreatic 
islets. Islets from human T2D cadaveric donors transduced to replenish STX4 
levels to that of non-diabetic islets showed fully restored biphasic insulin 
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secretion [9]. Furthermore, consistent with STX4 being limiting for function, 
biphasic insulin release was enhanced to supranormal levels in non-diabetic 
human islets transduced to overexpress STX4, and transplantation of a very 
minimal number of these islets (200 per graft) was capable of attenuating STZ-
induced diabetes [9]. This intriguing data support the concept of STX4 
enrichment as a potential novel therapeutic target for enhancing beta cell 
function in humans.  
1.9.3. STX4 Promotes Healthspan and Longevity  
Recent evidence has shown that beyond enhancing insulin secretion and 
glucose uptake, STX4 overexpression also promotes healthspan and longevity 
[109]. Transgenic mice overexpressing STX4 in pancreas, skeletal muscle, and 
adipocytes lived ~33% longer than wild-type control littermates [109]. 
Furthermore, when challenged with high fat diet-induced obesity, STX4 
transgenic mice showed preserved islet insulin secretion and skeletal muscle 
GLUT4 translocation compared to high fat-fed wild type mice [109]. Microarray 
analysis of muscle from the STX4 transgenic mice showed changes in pathways 
of leptin and AMPK signaling, as well as reduced Fox01 protein levels in 
pancreata. These intriguing results suggest that preservation of insulin sensitivity 
into old age, via retaining a rapid rate of glucose uptake/ clearance of excess 
circulating glucose, may protect against hyperglycemia-related damage to cells, 
diabetes, and improve overall healthspan and lifespan (Figure 1.5.).  
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Figure 1.5. Translational implications for SNARE/accessory proteins? 
Based on preliminary animal studies and in vitro analysis, targeting exocytosis 
proteins such as STX4 and DOC2B for enrichment appears to be beneficial in 
treatment strategies to deter aging/diminished healthspan, diabetes and cancer. 
N- denotes N-terminus; C- denotes C-terminus. 
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1.9.4. DOC2B as a restorative?  
Mice overexpressing DOC2B simultaneously in beta cells, skeletal muscle and 
adipocytes show a significantly increased capacity for glucose-stimulated insulin 
granule exocytosis and insulin-stimulated GLUT4 vesicle translocation [33]. 
While overexpressing DOC2B by only ~3 fold compared to endogenous levels, 
these transgenic mice were exquisitely insulin sensitive, showing supranormal 
levels of glucose tolerance (Table 1.3.). Importantly, despite the capacity of the 
islets to secrete 30-50% more insulin in response to a glucose bolus, the mice 
never exhibited hypoglycemia. This may be due to the rapid response of the 
skeletal muscle to the insulin release during first phase, triggering rapid glucose 
clearance and rapid return to normoglycemia, with this return being the natural 
cue for the pancreas to decrease release of insulin back to resting/basal levels. 
With this exquisite coordination and because of its ability to promote STX4 
activation, DOC2B over-expression presents an attractive target for restoring 
glucose homeostasis. The advantage to DOC2B is that it can enhance both 
phases of insulin release, and if delivered systemically, might enhance skeletal 
muscle insulin sensitivity concurrently. Whether DOC2B over-expression carries 
the capacity to protect against diabetogenic stimuli, remains to be tested. 
1.9.5. Stoichiometry 
Since overexpression of either STX4 or DOC2B potentiates selective exocytosis 
events in vivo and in clonal cells, STX4 and DOC2B are considered to be present 
in beta cells and muscle cells at limiting levels [28, 33, 60, 108, 126]. This 
concept is supported by quantification of stoichiometric ratios of STX4 and 
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SNAP23 in skeletal muscle from C57BL6 mice, where SNAP23 was found 
present in a 3-fold molar excess over that of STX4 [108], providing sufficient 
SNAP23 for appropriate stoichiometric ratios of t-SNARE binary complexes in the 
muscle of the STX4 overexpressing mice (STX4:SNAP23:VAMP2 assemble in a 
1:1:1 ratio [14]. DOC2B is not a SNARE protein per se, but its overexpression in 
skeletal muscle increased the abundance of STX4-based SNARE complexes, 
coordinate with an increase in DOC2B-Munc18c complexes and increased STX4 
activation [33]. This trio of effects is consistent with earlier cell culture findings 
pointing to DOC2B ‘freeing’ STX4 from Munc18c [56]. The only stoichiometric 
data reported on DOC2B comes from beta cells, wherein DOC2B was recently 
shown capable of binding in 1:1:1 ratio with Munc18-1 and Munc18c [26]. 
Stoichiometry of SNARE proteins and SNARE accessory factors still needs to be 
carefully quantified in primary tissue, although to date there is full consensus 
regarding beneficial effects of STX4 and DOC2B overexpression amongst 
primary islets and multiple different beta cell lines. Lastly, studies to investigate 
alterations in STX4 or DOC2B and their stoichiometry with other factors involved 
in proliferative and anti-tumorigenic mechanisms will require further investigation. 
Clearly, therapies designed to enhance STX4 and DOC2B could be clinically 
useful for a variety of metabolic aberrations (Figure 1.5.). 
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1.10. PERSPECTIVES: TARGETING EXOCYTOSIS PROTEINS FOR IDEAL 
DIABETES TREATMENT OUTCOMES 
Evidence suggesting that defects in exocytosis proteins precede onset of both 
T1D and T2D. Thus, these proteins may be ideal novel therapeutic targets for 
diabetes remediation. The ideal diabetes treatment outcomes for type 1 diabetes 
would be to enhance functional beta cell mass. T2D treatments ideally aim to 
enhance both functional beta cell mass and peripheral insulin sensitivity. It is thus 
plausible that proteins that can dually enhance functional beta cell mass and 
glucose uptake should be investigated for potential clinical relevance. Beyond 
functional enrichment, increasing evidence shows that exocytosis proteins may 
be involved in cell survival processes. For example, in neurons, it has been 
shown that STX1A and SNAP25 promote neuron survival via membrane 
recycling processes [127]. In lymphocytes, SNAP23 is limiting and necessary for 
B and T cell development and fibroblast survival [128]. SNAP25 has also been 
shown to play a role in neuronal spine morphogenesis and plasticity [129]. 
Protection of beta cell mass and promotion of survival are certainly ideal 
outcomes for a diabetes therapeutics, and should be kept in mind when 
developing novel drugs. 
 
What are the potential perils to overexpressing SNARE/accessory proteins? With 
increasing evidence that exocytosis proteins may be involved in cell survival 
processes, there is controversy regarding exocytosis proteins involvement in 
tumorigenesis. Some studies have shown that certain SNAREs may facilitate 
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tumor cell migration, mediate inflammation involved in cancer development, and 
may be under regulation by oncogenes [130]. Despite this, both STX4 and 
DOC2B have been shown to possess pro-apoptotic/anti-cancer properties [102, 
103], indicating that isoform-type and context-type specificities are crucial to 
determine when considering replenishment or over-expression strategies for 
treatment/prevention of diabetes and/or cancer. 
  
1.11. RATIONALE AND CENTRAL HYPOTHESIS 
The rationale for investigating the role of exocytosis proteins as targets for 
preventing/treating T1D is that increasing evidences link deficiencies of 
exocytosis proteins to diabetes in humans and rodents [8, 79, 82, 84, 86, 94]. 
Furthermore, studies aimed to enhance exocytosis proteins such as DOC2B and 
STX4 has resulted in promising outcomes that point to the ability to maintain 
functional β-cell mass. This dissertation will hereto forth focus on DOC2B. I will 
also focus on T1D and the inflammatory aspects of -cell dysfunction and demise 
that are common to both T1D and T2D. My central hypothesis is that DOC2B 
abundance in the islet -cell is compromised during development of T1D, and 
that early -cell specific enrichment of DOC2B will protect/improve functional 
beta cell mass and survival to delay/prevent T1D onset. I tested this hypothesis 
via two Specific Aims: 1) Determine the relationship between DOC2B abundance 
and new-onset T1D in humans and rodent model systems; and 2) Determine the 
effect of enriched DOC2B on functional β-cell mass in vivo, and resistance to 
diabetic stress in β-cell specific transgenic rodent models and human islets.  
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CHAPTER 2 
 
EXOCYTOSIS PROTEIN DOC2B AS A BIOMARKER OF TYPE 1 DIABETES 
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2.1. SYNOPSIS 
Efforts to preserve and protect β-cell mass in the preclinical stages of type 1 
diabetes (T1D) are limited by few blood-borne biomarkers of β-cell destruction. 
We demonstrate here that the β-cell exocytosis protein, Double C2 domain 
protein (DOC2B) abundance is substantially reduced in prediabetic NOD mouse 
platelets, and these changes are mirrored in the pancreatic islets from the same 
mice. Similarly, human DOC2B levels were reduced over 2-fold in platelets from 
new-onset T1D human subjects, and this reduction was mirrored in T1D human 
islets. Cytokine stimulation of normal islets reduced DOC2B expression ex vivo. 
Remarkably, platelet DOC2B levels increased after islet transplantation in T1D 
patients. These data suggest that reduction of DOC2B is an early feature of T1D, 
and DOC2B abundance may serve as a valuable in vivo indicator of β-cell mass 
and early biomarker of T1D. 
 
2.2. INTRODUCTION 
Diabetes mellitus is a complex metabolic disorder that currently affects an 
estimated 422 million people worldwide, with incidence rates steadily rising [131]. 
Type 1 diabetes (T1D) accounts for 5-10% of these cases. Its complications 
remain a major cause of global morbidity and mortality. T1D is characterized by 
autoimmune destruction of β-cell mass, and the preclinical phase of T1D is 
marked by declining β-cell function [92, 93]. Studies of early intervention in T1D 
have shown limited effectiveness, yet have generally shown greater success in 
subjects that retain greater insulin secretory capacity, and in those with the 
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shortest time since clinical onset of disease [132, 133]. However, prevention 
efforts to protect β-cell mass are hindered by the limited availability of early 
biomarkers to accurately predict β-cell destruction and subsequent progression 
to clinical disease. 
 
In healthy β-cells, insulin secretion requires soluble N-ethylmaleimide-sensitive 
factor-attachment protein receptor (SNARE) proteins and associated accessory 
regulatory proteins to promote the docking, priming, and fusion of insulin vesicles 
at the plasma membrane. Two target membrane (t)-SNARE proteins, 
Syntaxin1/4 and SNAP25/23, and one vesicle-associated (v-SNARE) protein, 
VAMP2, constitute the SNARE core complex [134]. Assembly of the SNARE 
complex occurs when one v-SNARE binds two cognate t-SNARE proteins in a 
heterotrimeric ratio [14]. SNARE complex assembly is also facilitated by the 
accessory regulatory protein, Double C2-domain  (DOC2B) [28, 60]. Several 
studies have established that in animal models, deficiencies in DOC2B result in 
glucose intolerance and insulin secretion defects [24, 25]. Conversely, 
overexpression of DOC2B using a global transgenic mouse model enhances 
insulin secretion and peripheral glucose uptake [33]. Although DOC2B deficiency 
in rodents has been linked to type 2 diabetes [135], the association between 
DOC2B protein levels and T1D is still unknown. 
 
Deficient first-phase insulin secretion is a hallmark of preclinical T1D [92, 93]; 
thus, the ability to assess early pancreatic -cell destruction is critically important 
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for predicting disease onset. Currently, risk prediction for T1D relies heavily on 
family history, genetic screening, and the presence of antibodies against β-cell 
antigens that often appear relatively late in the progression of disease. The use 
of autoantibodies in evaluating T1D risk is limited, as >50% of autoantibody-
positive patients remain disease-free, even at 5 years follow up [136]. Risk 
scores have been established [137], but remain insufficient to provide an 
accurate prognosis, nor an accurate measurement of -cell health, as many 
autoantibody-positive individuals are slow to progress through the stages [138] of 
preclinical disease. To improve early prediction of T1D, ongoing studies seek to 
investigate the levels of circulating factors that reflect declining -cell health, such 
as proinsulin [139], HSP-90 [140], and unmethylated insulin DNA [141] as 
potential biomarkers of T1D.  
 
Another potential source of biomarkers is the blood-derived platelet, which is 
currently being investigated in diseases such as Alzheimer’s disease [142] and 
cancer [143], and has been implicated in T1D. Changes in the platelet proteome 
and morphology have been noted in T1D; for instance, altered intracellular Ca2+ 
[144], enhanced formation of microparticles [145], and altered morphology [146] 
have been reported to result in platelet hyper-reactivity and development of 
vasculopathies. Importantly, platelets harbor many of the same exocytosis 
proteins as the pancreatic -cell, including SNARE isoforms and accessory 
regulatory proteins [147].  
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Biomarkers of β-cell destruction in blood have more clinical potential than those 
in pancreatic islets, as islet procurement is not feasible for routine diagnosis; 
therefore, we investigated the correlation between DOC2B protein abundance in 
blood-derived platelets and pancreatic islets in NOD mice and T1D humans. We 
found that protein abundance of DOC2B is reduced in platelets and islets from 
prediabetic NOD mice, compared to control mice. Furthermore, DOC2B protein 
abundance is reduced in platelets and islets from humans with new-onset T1D, 
compared to matched controls. Notably, we also reveal that DOC2B levels are 
substantially increased in T1D human platelets after islet transplantation, when 
C-peptide levels were markedly increased. 
 
2.3. MATERIAL, SUBJECTS, AND METHODS 
 2.3.1. Animals 
Animals were maintained under protocols approved by the Indiana University 
Institutional Animal Care and Use Committee and following the National 
Research Council Guidelines for the Care and Use of Laboratory Animals. 
Female non-obese diabetic (NOD) NOD/ShiLtJ (RRID:IMSR_JAX:001976) and 
major histocompatibility complex (MHC)-matched control non-obese diabetes 
resistant (NOR) (RRID:IMSR_JAX:002050) mice were obtained from the Jackson 
Laboratory (Bar Harbor, Maine). We have observed that female NOD mice begin 
to convert to T1D at 17-18 weeks of age, with an average conversion rate of 78% 
by 20 weeks of age, as previously reported [148]. Random blood glucose 
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analysis was performed weekly to monitor conversion to T1D, which is 
characterized by non-fasting blood glucose levels >250 mg/dl for three 
consecutive days. To assess DOC2B levels before conversion to T1D, 
pancreatic islets were isolated, using a method as described previously [9], at 7 
weeks (earliest time point for sufficient islet cell yield), 13 weeks (intermediate 
time point), and 16 weeks of age (latest time point before conversion to T1D). 
Islet isolation yield decreases in mice less than 8 weeks of age [149]. Islet 
lysates were then used for SDS-PAGE and immunoblotting. Mouse blood was 
collected (from 13 and 16 week old mice; blood was insufficient from 7 week old 
mice) and platelets were isolated as previously described [147]. Platelet lysates 
were then used for SDS-PAGE and immunoblotting.  
2.3.2. Human Subjects  
This protocol was approved by the Indiana University Institutional Review Board. 
For evaluation of DOC2B levels in human platelets (new-onset T1D study), 
subjects aged 8-14 (11 males and 6 females) with new-onset T1D were recruited 
over an 18-month period.  Consent was obtained from parents, with assent from 
the pediatric subjects. Subjects were diagnosed with T1D if they met the criteria 
of 1 or more positive autoantibodies with clinical features of T1D: hyperglycemia, 
weight loss, and normal body mass index (BMI), or those who were autoantibody 
negative but <10 years old at diagnosis. Exclusion criteria were as previously 
described [140]. For each visit, subjects received $25. Subjects had blood drawn 
at diagnosis and at the first follow-up appointment 7-10 weeks after diagnosis. 
Insulin treatment of T1D subjects was started at time of diagnosis. Non-diabetic 
 45 
 
control subjects (8 males and 6 females) were recruited from the community and 
matched to T1D subjects based on gender, age, and BMI (see Table 2.1. for 
demographic data).  
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Table 2.1. Pediatric T1D study demographics 
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; T1D, type one 
diabetes. Values displayed are means ± standard deviations unless otherwise 
noted. *For BMI calculations, 1 T1D subject did not have a diagnosis height and 
1 non-T1D control did not have a registration height. For these subjects heights 
from clinic follow-up were used to calculate BMI. †The following 3 diabetes-
associated antibodies were tested: GAD, miAA, and IA-2A. ‡ For C-peptide at 
diagnosis, n=13. 
  
     
Characteristic Non-T1D 
controls 
T1D subjects 
      
Number of subjects 14 17 
Age (y), (range) 11.4 y (8.0-
14.3) 
10.3 y (4.3-14.1) 
Sex (male)  55% 57% 
BMI (Kg/m2)* 20.2 ± 3.0 17.5 ± 2.8 
Number of autoantibodies 
positive † 
---- 0 AutoAb positive: 
1 
1 AutoAb positive: 
5 
2 AutoAb positive: 
9 
3 AutoAb positive: 
2 
Basal insulin requirement 
prior to hospital discharge 
(units/kg/d) 
---- 0.30  ± 0.09 
C-peptide at diagnosis 
(pmol/l) ‡ 
 110 ± 169 (13-
608) 
HbA1c at diagnosis (range)  ---- 
 
11.0 ± 1.7% (7.5 ± 
14.2) 
HbA1c at first follow-up 
(range)  
---- 7.7 ± 0.8% (6.4-
9.0) 
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Samples were de-identified and coded by the clinical team prior to distribution to 
the research lab for platelet isolation and analyses. Platelets were isolated by 
centrifugation from blood, as previously described [150], and lysed for SDS-
PAGE and immunoblotting. Upon quantification of the data for each sample, the 
clinical team re-identified samples to permit grouping of data into T1D vs non-
diabetic for statistical comparisons. 
 
For evaluation of DOC2B levels in human islets (T1D islet transplantation study), 
samples were obtained from T1D islet transplantation recipients, as approved by 
the City of Hope Institutional Review Board. Two subjects, aged 43 and 52 years, 
were recruited for human islet transplantation based on the following criteria: T1D 
diagnosis with frequent or life-threatening hypoglycemia with or without 
unawareness symptoms. Blood was obtained from both subjects prior to 
transplantation (Day 0), and on Days 30, and 75 after islet transplantation (see 
Table 2.2. for demographic data). Platelets were isolated by centrifugation from 
blood, as previously described [150], and lysed for SDS-PAGE and 
immunoblotting. 
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Table 2.2. Baseline adult islet transplant recipient and islet graft 
characteristics 
 
Abbreviations: PRA, panel reactive antibody; IEQ, islet equivalent. 
  
  Islet Transplant Recipients 
Characteristics COH-027 COH-028 
Recipient 
Characteristics 
    
Sex F M 
Age  at transplant 
(years) 
43 52 
Weight (kg) 76.5 92 
BMI (kg/m2) 28.93 29.77 
Duration of diabetes 
(years) 
33 34 
HbA1c (%) 5.5 8.5 
Insulin intake 
(units/day) 
28 52 
Fasting/Glucagon-
Stimulated C-peptide 
(ng/ml) 
0.03/0.02 <0.02/<0.02 
Autoantibodies GAD65-neg | IA-2-pos 
mIAA-pos | ZnT8-neg 
GAD65-pos | IA-2-neg 
mIAA-pos | ZnT8-neg 
PRA Class I/Class II 
(%) 
0/0 0/0 
Islet Graft 
Characteristics 
  
Islet Dose  (IEQ)   
Total IEQ 240,133 482,755 
IEQ/kg 3,139 5,247 
Islet Purity (%) 50 68 
Packed Cell Volume 
(ml) 
1.9 2.8 
Islet Viability (%) 91 94 
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2.3.3. Islet cell transplantation  
For the T1D islet transplant study, human pancreata were procured from ABO-
compatible, cross-match negative cadaveric donors. The islets were isolated 
under cGMP conditions by the Southern California Islet Cell Resource Center at 
City of Hope using a modified Ricordi method. Islets were maintained in culture 
for up to 72 hours prior to transplantation. Islets were transplanted intraportally 
with heparinized saline (35 U/kg recipient body weight) using a transhepatic 
percutaneous approach.  
2.3.4. Clinical//laboratory assays  
For the new-onset T1D study, autoantibodies to glutamic acid decarboxylase 65 
(GAD-65), insulin, and Islet Antigen 2 (IA2) were assayed from peripheral blood 
at diagnosis at Mayo Medical Laboratories (Rochester, Minnesota). Glycated 
hemoglobin (HbA1c) was also measured at diagnosis and at first clinic follow-up 
(7-10 weeks after diagnosis) using the Bayer A1cNow system or the Bayer 
DCA2000 analyzer (Tarrytown, New York). C-peptide was measured in stored 
serum samples using the C-peptide ELISA kit (Alpco, Salem, New Hampshire; 
detection range 20-3000 pM). 
 
For the T1D islet transplant study, plasma C-peptide measurements were 
performed by the Northwest Lipid Metabolism and Diabetes Laboratory (Seattle, 
WA) using the Tosoh C-Peptide II Assay (Tosoh Bioscience, Inc, San Francisco, 
CA; detection range 0.02-30 ng/ml). A fasting C-peptide < 0.2 ng/ml and 6-min 
glucagon-stimulated C-peptide < 0.3 ng/ml were used to confirm T1D diagnosis 
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prior to islet transplant. Autoantibodies (GAD-65, IA-2A, insulin [mIAA], and zinc 
transporter 8 [ZnT8]) were analyzed using radiobinding assays by the 
Autoantibody/HLA Service Center at the Barbara Davis Center for Diabetes 
(Aurora, CA).  
2.3.5. Ex vivo islet preparations  
Non-T1D human cadaveric pancreatic islets were obtained through the 
Integrated Islet Distribution Program at City of Hope. The islets were prepared 
and treated with a cytokine mixture (10 ng/ml TNF-, 100 ng/ml IFN- and 5 
ng/ml IL-1 ; ProSpec, East Brunswick, NJ, USA) for 72 hours, as previously 
described [151]. The islets were then used in qRT-PCR analysis or SDS-PAGE 
followed by immunoblotting.  
2.3.6. Immunofluorescence  
Human paraffin-embedded pancreatic tissue sections were obtained from the 
Network for Pancreatic Organ Donors with Diabetes (nPOD). Five sections from 
formalin-fixed paraffin-embedded (FFPE) tissue samples were obtained from 
T1D (n=3) and age and BMI-matched non-diabetic (n=3) donors. Pancreas 
sections were immunostained with primary and secondary antibodies listed in 
Table 2.3. Slides were counterstained to mark the nuclei, using 4’,6- diamidino-2-
phenylindole (DAPI) (Vectashield; Vector Laboratories, Burlingame, CA) and 
viewed using a Keyence BZ X-700 fluorescence microscope (Keyence 
Corporation, Itasca, IL). All human T1D samples were prepared and processed 
at the same time; confocal images were taken with identical acquisition settings. 
Islet immunofluorescence was assessed by imaging 20-30 islets (grouping of 
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four or more insulin-positive cells) per subject. Analysis was performed in a 
blinded fashion using Image-Pro Software (Media Cybernetics, Rockville, MD, 
USA) to quantify fluorescence intensities using methods as previously described. 
[152] Defined regions of interest (ROIs) were used to delimit islets from adjacent 
acinar tissue and average intensity measurements of insulin and DOC2B were 
quantified by splitting the merged image into two color channels with the same 
ROI.  
2.3.7. Immunoblotting  
Platelet and islet protein lysates for the NOD mouse study were resolved on a 
10% SDS-PAGE gel and transferred to standard PVDF (Bio-Rad, Hercules, CA, 
USA). Platelet proteins from the new-onset T1D study were resolved on a 10% 
SDS-PAGE gel using an SE400 air-cooled 18 x 16 cm vertical protein 
electrophoresis unit (Hoefer, Inc. Holliston, MA) and transferred to standard 
PVDF (Bio-Rad). Platelet proteins from the T1D islet transplant study were 
resolved on a 12% SDS-PAGE gel using a CriterionTM 13.3 x 8.7 cm vertical 
electrophoresis unit (Bio-Rad) and transferred to standard PVDF. All blots were 
probed as outlined in Table 2.3. 
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Table 2.3. Primary and secondary antibodies used in study 
 
 
 
 
 
 
Protein Target  Source  Catalogue No.  RRID No. 
Primary antibodies used in NOD mouse study/ex vivo islet study 
DOC2B Proteintech 20574-1-AP AB_10696316 
Tubulin Abcam ab56676 AB_945996 
iNOS Millipore ABN26 AB_10805939 
Primary antibodies used in New-onset T1D/T1D transplant study 
DOC2B Abnova  H00008447-B01P AB_10549446 
GAPDH  Abnova  ab9485 AB_307275 
Primary antibodies used in immunofluorescence study 
 
DOC2B Proteintech 20574-1-AP AB_10696316 
Insulin Abcam ab7842) AB_306130 
Secondary antibodies  
goat anti-rabbit  Bio-Rad  1706515 AB_11125142 
goat anti-mouse Bio-Rad 1706516 AB_11125547 
Alexa Fluor 568 
goat anti-rabbit 
Abcam ab175471 AB_2576207 
Alexa Fluor 488 
goat anti-guinea 
pig 
Thermo A-11073 AB_2534117 
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2.3.8. Quantitative real-time PCR 
Total RNA was isolated from human islets using the Qiagen RNeasy Plus Mini 
Kit (Qiagen, Valencia, CA, USA) and assessed using the QuantiTect SYBR 
Green RT-PCR kit (Qiagen). Primers used for the detection of hDoc2b are as 
follows: forward: 5’-CCAGTAAGGCAAATAAGCTC-3’ and reverse: 5’-
GGGTTTCAGCTTCTTCA-3’. Standard tubulin primers (Cat:QT00089775, 
Qiagen) were used for normalization. 
 2.3.9. Statistical analysis 
Data were evaluated for statistical significance using Student’s t test for 
comparison of two groups; ANOVA and Tukey’s post-hoc test (GraphPad 
Software, La Jolla, CA, USA) were used for comparison of more than two groups. 
Data are expressed as the average ± SEM. 
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2.4 RESULTS 
2.4.1. Low DOC2B levels in pre-diabetic NOD mouse platelets and 
islets 
To investigate whether DOC2B protein levels are altered in the blood prior to 
onset of T1D, we examined platelet DOC2B abundance in young pre-diabetic 
NOD mice and MHC-matched NOR mice. Immunoblotting revealed that platelets 
from 16- and 13-week old NOD mice exhibited up to a 90% reduction in DOC2B 
protein levels (Figure 2.1.A) compared to NOR platelets. Furthermore, islets from 
16- and 13-week old NOD mice showed at least a 65% reduction in DOC2B 
protein levels (Figure 2.1.B.) compared to NOR islets. NOD islets from as early 
as 7 weeks of age showed a 90% reduction in DOC2B protein (Figure 2.1.B). 
The average blood glucose levels from random blood testing of NOD and NOR 
mice were below 250 mg/dL at 7, 13, and 16 weeks (Table 2.4.), indicating that 
the mice had not yet converted to diabetes. These data show that DOC2B 
protein abundance is reduced in both islets and platelets of prediabetic mice.  
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Figure 2.1. DOC2B protein abundance is reduced in platelets of pre-diabetic 
NOD mice. Platelets were isolated from 16 or 13 wk old group-housed female 
NOD and age-matched NOR mice and proteins were resolved on SDS-PAGE for 
immunoblotting. DOC2B levels were quantified relative to tubulin immunoblotting 
in the same lane. Dashed vertical lines indicate splicing of lanes from within the 
same gel exposure. Islets were isolated from 16, 13 or 7 wk old group-housed 
female NOD and age-matched NOR mice and proteins were resolved on SDS-
PAGE for immunoblotting. DOC2B levels were quantified relative to tubulin 
loading in the same lane. Dashed vertical lines indicate splicing of lanes from 
within the same gel exposure. Data are shown as means ± SEM (n=3-6 mice per 
group); *p<0.05.   
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Table 2.4.: Average blood glucose levels of NOD and NOR mice at 16, 13, 
and 7 weeks. Data represent the average  S.EM; n=6 per group for mice at 16 
and 13 weeks; n=5 per group at 7 weeks. Random non-fasting blood glucose 
was measured for NOR and NOD female mice at 13 and 16 weeks of age. No 
statistical differences were seen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Avg. Non-fasting Blood Glucose 
(mg/dL) 
 
16 wks 13 wks 7 wks 
NOR 197  17 183  10 130  6 
NOD 196  19 194  22 127  5 
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2.4.2. Low DOC2B levels in new-onset T1D human platelets 
In the new-onset T1D study, we quantified protein content of DOC2B using 
platelets from new-onset T1D subjects in comparison to controls (Table 2.1.). 
Platelets from new-onset T1D subjects exhibited reduced protein levels of 
DOC2B for both sexes, both at diagnosis and at first clinic follow-up 7-10 weeks 
later. When males and females were assessed separately, DOC2B levels were 
reduced in males by 60% compared to non-diabetic control subjects, persisting 
even after insulin treatment of the patient and reduction of HbA1c (Figure 2.2.). 
The significant loss of DOC2B at T1D diagnosis was selective for DOC2B 
compared to another exocytosis protein, syntaxin 4 (STX4) (Figure 2.3.). These 
data indicate that DOC2B is decreased in T1D platelets independent of glycemic 
control, relative to non-diabetic human platelets, and that platelet DOC2B levels 
are already diminished at T1D diagnosis.  
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Figure 2.2. Platelets were isolated from new-onset T1D patients at the time of 
diagnosis (“Diagnosis”) and 7-10 weeks later (“First Follow-up”), and from 
matched controls (“Control”). Platelet proteins were resolved on SDS-PAGE for 
immunoblotting. Standard curves were generated using recombinantly-expressed 
and purified human DOC2B protein on each gel to confirm that the the band 
intensities of DOC2B in human platelets fell within the dynamic range of the 
curve on the same gel. DOC2B was quantified relative to protein loading 
determined by Ponceau S staining in the same lane (37-68 kDa segment). 
Dashed vertical lines indicate splicing of lanes from within the same gel exposure. 
Data are shown as means ± SEM for DOC2B (n=11-14 per group [gender-
combined group, 8 males per group, 3-6 females per group); *p<0.05, Diagnosis 
vs. Control.; #p<0.05 Follow-up vs. Control).  
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Figure 2.3. Human Platelet STX4. Platelet proteins from children with T1D and 
age/gender/BMI matched controls were isolated at Diagnosis and First Follow-up 
7-10 weeks later, then resolved on SDS-PAGE for immunoblotting for STX4. 
Standard curves were included using recombinantly-expressed and purified 
human STX protein on each gel with band intensities of STX4 in human platelets 
falling within the dynamic range of the curve on the same gel. Dashed vertical 
lines indicate splicing of lanes from within the same gel exposure. Data are 
shown as means ± SEM. n=10-13 per gender-combined group, 5-7 males per 
group, 3-6 females per group); *p<0.05, Diagnosis vs. Control.; #p<0.05 Follow-
up vs. Control.  
IB: STX4 
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2.4.3. Ex vivo pro-inflammatory cytokine treatment reduces human 
islet DOC2B levels 
T1D is associated with elevated circulating pro-inflammatory cytokines, which 
damage β-cells [153]. Because obtaining pancreatic islets from living T1D 
subjects is virtually impossible, we evaluated the relationship between T1D and 
DOC2B levels by treating human cadaveric non-diabetic islets (Table 2.5.) ex 
vivo with pro-inflammatory cytokines in effort to simulate the circulating milieu. 
Cytokine treatment (IL-1, TNF-, INF-) elevated the levels of islet iNOS (Figure 
2.4.A), consistent with the reported effects of cytokine exposure [154]. 
Correspondingly, DOC2B protein and mRNA levels were reduced by 30% and 
50%, respectively (Figure 2.4.A-B). These data suggest that a T1D-like milieu 
can decrease DOC2B levels in human islets.  
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Figure 2.4. DOC2B protein and mRNA abundance is reduced in adult 
human islets subjected to treatment with pro-inflammatory cytokines. 
Human adult cadaveric islets were incubated under control conditions or with 
pro-inflammatory cytokines for 72 h at 37oC. Islet protein lysates were resolved 
by SDS-PAGE for immunoblotting (a) or for RNA extraction and qRT-PCR 
analysis (b). In addition to hDOC2B, tubulin and iNOS levels were also evaluated 
by immunoblotting. Bars represent mean ± SEM for 4 or 5 independent sets of 
human islets evaluated for protein and mRNA analyses, respectively; 
****p<0.0001, **p<0.002.  
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Unos/COH 
ID no. 
Sex Age BMI Race Islet 
purity 
Islet 
viability 
Exp. 
use 
ACIN402 M 49 40.0 Hispanic N/A N/A protein 
ACIY103 M 24 24.6 Caucasian 78% N/A protein 
Hu966 M 20 30.6 African 
American 
88% N/A protein 
ADBL F 53 23.8 Caucasian 90% 90% protein 
                
ADFE489 F 45 23.1 Asian N/A N/A mRNA 
ADDV480 M 52 25.4 Caucasian N/A N/A mRNA 
AEFU443 F 49 29 Caucasian 95% 95% mRNA 
Hu1000 M 49 29 Hispanic N/A N/A mRNA 
Hu966 M 20 30.6 African 
American 
88% N/A mRNA 
ACIY103 M 24 24.6 Caucasian 78% N/A mRNA 
Table 2.5. Non-diabetic human islet donor characteristics 
Abbreviations: NA= data not available. 
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2.4.4. Reduced DOC2B protein in human early-onset T1D islets. 
To investigate changes in DOC2B levels in T1D human pancreata, we used 
paraffin-embedded slides (obtained from nPOD [Network for Pancreatic Organ 
Donors with Diabetes]) from cadaveric donors for DOC2B immunofluorescence 
evaluation in early-onset pediatric T1D (5 years or less with T1D) (n=3) versus 
matched non-diabetic (ND) controls (n=3) (Figure 2.5.A, and Table 2.6.). 
Measuring relative immunofluorescent intensities, we observed a decrease in 
DOC2B abundance in T1D islets versus than in non-diabetic controls (Figure 
2.5.B). Although the relative number of DOC2B-positive -cells in non-diabetic 
and T1D islets were similar (Figure 2.5.C), DOC2B intensity was reduced in T1D 
β-cells. 
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Figure 2.5. DOC2B protein levels are reduced in islets of pediatric T1D 
humans. Slides obtained from nPOD, comprised of early-onset T1D and age-
matched non-diabetic human pancreata, were immunostained for the presence 
of DOC2B or insulin in DAPI-positive cells. A) representative images, low power 
images scale bar=100 m, higher magnification images scale bar=25 m. B) 
tabulated relative intensities; n = 3 donors, *p<0.05. C) Number of DOC2B-
positive β-cells p=not significant, (N.S.). 
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nPOD ID no. Sex Age BMI Race Years 
of T1D 
6113 F 13.1 24.7 Caucasian 1.5 
6342 F 14 24.3 Caucasian 2 
6243 M 13 21.3 Caucasian 5 
6386 M 14 23.9 Caucasian ND 
6392 M 14.1 23.6 Caucasian ND 
6340 M 9.7 20.3 Caucasian ND 
 
Table 2.6. nPOD sample human pancreata donor characteristics.  
Abbreviations: ND; non-diabetic 
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2.4.5. DOC2B levels restored after clinical islet transplantation. 
In the T1D islet transplantation study (Table 2.2.), we found that the pre-
transplant platelet DOC2B levels were very low in both subjects relative to a 
hDOC2B protein standard curve (Figure 2.6.A-B, Day 0). Notably, within 30 days 
of transplantation, each T1D islet recipient showed a robust increase in platelet 
DOC2B protein, which persisted to 75 days after transplantation (Figure 2.6.A-B, 
Days 30 and 75). These data coincide with changes in C-peptide levels in these 
subjects: while each subject had low to almost undetectable fasting/glucagon-
stimulated C-peptide levels before transplantation, the C-peptide levels were 
substantially increased by 30 days after transplantation (Table 2.6.). As C-
peptide levels are indicative of overall islet function, these data suggest that in 
humans, DOC2B levels in platelets correlate with relative functional β-cell mass. 
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Figure 2.6. DOC2B levels in adult T1D human platelets are increased after 
clinical islet transplantation. Platelets obtained from two clinical islet transplant 
recipients prior to (Day 0) islet infusion, or on Days 30 and 75 post-infusion, were 
evaluated by quantitative immunoblotting for DOC2B protein content: (a) subject 
COH-027, (b) subject COH-028. Ponceau S staining and GAPDH show the 
relative protein loading of the membranes used for immunoblotting.  
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 Islet Transplant Recipients 
 COH-027 COH-028 
Immunosuppression Regimen Induction: 
rATG, etanercept, anakinra 
Maintenance:   
tacrolimus, MMF, +/-
sirolimus 
Induction: 
rATG, etanercept, 
anakinra,  
Maintenance:  
tacrolimus, MMF +/- 
sirolimus 
Additional Immunosuppression 
for suspected islet graft rejection 
Solumedrol, 
Plasmapheresis, IVIg & 
Rituxan for suspected islet 
graft rejection 
NA 
HbA1c (%)                                        
Pre-Tx 
5.5 8.5 
Day 30 ND ND 
Day 75 5.3 6 
Insulin intake (units/day)              
Pre-Tx 
28 52 
Day 30 13 28 
Day 75 15 8 
Fasting/Glucagon-Stimulated  
C-peptide (ng/ml) 
  
Pre-Tx 0.03/0.02 <0.02/<0.02 
Day 30 2.78/3.56 1.71/3.39 
Day 75 0.84/1.42 1.23/2.40 
Mixed Meal Tolerance Test 
(MMTT) 
C-peptide at 0/90min 
  
Pre-Tx ND ND 
Day 30 ND ND 
Day 75 0.63/2.65 1.62/2.95 
Oral Glucose Tolerance Test 
(OGTT) 
BG (mg/dl)  | C-pep (ng/ml , 
Fasting/120min 
  
Pre-Tx ND ND 
Day 30 BG: 102/197 | C-pep: 
1.49/6.72 
BG: 127/228 | C-pep: 
1.65/4.81 
Day 75 BG: 101/199 | C-pep:  
0.71/3.52 
BG: 148/310 | C-pep: 
1.46/3.22 
Autoantibodies                               
Pre-Tx 
GAD65-neg   /  IA-2-pos 
mIAA-pos  /  ZnT8-neg 
GAD65-pos  /  IA-2-neg 
mIAA-pos  /  ZnT8-neg 
Day 75 GAD65-pos*  /  IA-2-pos 
mIAA-neg*  /  ZnT8-neg 
GAD65-pos  /  IA-2-neg 
mIAA-pos  /  ZnT8-neg 
Table 2.6. Islet transplant recipient treatment and outcome summary. 
Abbreviations: NA, Not applicable; ND, Not done; Pre-Tx: Pre-Transplant 
(baseline); 
*Denotes change in auto or allo-antibodies status from baseline  
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2.5. DISCUSSION 
The ability to detect β-cell destruction is critical in accurately predicting prognosis 
during the preclinical phase of T1D, hence the current need for additional early 
biomarkers. We show that DOC2B protein levels are substantially reduced in 
platelets and islets from pre-diabetic NOD mice vs. NOR control mice. 
Furthermore, we reveal that levels of human DOC2B are significantly lower at the 
time of diagnosis in platelets of new-onset T1D pediatric patients than platelets 
from matched control subjects. Notably, DOC2B levels were reduced at 7-10 
weeks post-diagnosis, despite therapeutic remediation of hyperglycemia in the 
human subjects. Consistent with this, islet DOC2B protein levels were reduced in 
early onset T1D pancreatic tissue samples compared to matched controls. Loss 
of DOC2B protein and mRNA could be recapitulated by exposure of non-diabetic 
human islets to pro-inflammatory cytokines ex vivo, suggesting that the 
inflammatory milieu in pre-diabetic and T1D humans may cause DOC2B loss. 
Remarkably, clinical islet transplant recipients exhibit a restoration of DOC2B 
levels in platelets, compared with their own nearly undetectable levels of platelet 
DOC2B prior to receiving the transplanted islets. These data suggest that 
DOC2B protein is a candidate biomarker of pre-diabetes and T1D, with the levels 
possibly reporting relative functional β-cell mass.  
 
To our knowledge, this is the first study to establish an association between T1D 
and levels of an exocytosis protein in blood-derived platelets and pancreatic 
islets. Reduced DOC2B in islets is indicative of deficient islet functional health 
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[24]. Strikingly, platelet DOC2B levels in islet transplant recipients correlated with 
the presence of a functional islet mass. This correlative finding supports the 
possibility that the platelet DOC2B stems not necessarily from the pancreas per 
se, since islets are grafted into the liver in these human recipients, but that the 
platelets and/or precursor megakaryocytes may be sampling DOC2B from the 
islets irrespective of islet location. It also remains possible that the increased 
DOC2B content stems from ‘rested’ native residual islets of the transplanted 
patients. However, this is inconsistent with our pediatric platelet data showing 
that even after insulin therapy to ameliorate new-onset hyperglycemia, DOC2B 
levels remained deficient. Mechanistically, questions arise as to if and how 
platelets and islets communicate to determine DOC2B levels. Supporting the 
concept of platelet-islet communication, it has been demonstrated that islet 
transplantation in T1D patients stabilizes platelet abnormalities, as transplant 
recipient platelets show normal volume and activation [155]. Indeed, -cells 
release exosomes as a way of shuttling various miRNAs, mRNAs, and proteins 
to targeted peripheral cells [156]. -cell exosomes were also recently shown to 
carry proteins, such as GAD-65, IA-2, and proinsulin, to dendritic cells, which 
then become activated [157]. Could islets similarly release DOC2B mRNA or 
protein, which is subsequently taken up by megakaryocytes or by the platelets 
themselves? Furthermore, platelets can selectively absorb proteins from the 
blood [158]. In fact, platelet sequestration of tumor-specific proteins was detected 
in animals harboring small tumors [158]. Notably, a direct interaction between 
platelets and pancreatic β-cells has been reported, and protein from platelets 
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was shown to be transferred to β-cells [159]. Is it possible that the platelets are 
sampling the islets to mirror islet DOC2B levels? As the data presented herein 
are correlative in nature, future studies will be required to determine the detailed 
molecular mechanism regulating changes in DOC2B protein abundance in 
human T1D samples. 
 
The concept of DOC2B as a biomarker is appealing because DOC2B levels in 
platelets and islets are significantly decreased in normoglycemic NOD mice 
months before their conversion to T1D. Female NOD mice typically convert to 
T1D between 18-24 weeks of age, but as early as 5 weeks of age, NOD mouse 
islets show signs of insulitis, resulting from an initial phase of pancreatic 
inflammation that reduces β-cell function and mass [160]. Given that DOC2B 
content in human islets decreased upon islet exposure to pro-inflammatory 
cytokines, which was sufficient to evoke iNOS expression, it is possible that the 
cytokine-induced drop in islet DOC2B signals reduced islet viability. Although it 
has been demonstrated by multiple groups that whole-body DOC2B knockout 
mice show deficient glucose-stimulated insulin secretion [24, 25], β-cell mass 
was not evaluated. While it is also possible that DOC2B expression is genetically 
repressed in NOD mice, the genetics of NOD mice have been well studied and 
DOC2B was not identified as deviating from control [161]. DOC2B mRNA 
expression was also decreased in response to pro-inflammatory cytokine 
exposure in non-diabetic human islets, suggesting that DOC2B might undergo 
transcriptional repression during T1D development. Indeed, promoter methylation 
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and silencing of DOC2B gene have been reported to occur in cancer cell types 
[103]. Future studies will be required to determine the detailed molecular 
mechanism regulating changes in DOC2B protein abundance in human T1D 
samples.  
 
While novel findings were obtained, there are also some limitations to the 
conclusions that can be derived from this study. First, this work derives from two 
pilot studies with relatively small sample sizes of human pediatric subjects (N=14 
controls and N=17 T1D patients; new-onset T1D study) and adult T1D islet 
transplant subjects (N=2; T1D islet transplantation study). Secondly, the pediatric 
cohort was evaluated at clinical diagnosis of T1D, so these patients already have 
full-blown disease. A larger future study would benefit from a prospective design 
that includes subjects who are significantly at risk, but who are normoglycemic. 
We are also limited in that only the first clinical follow-up samples were obtained, 
and we do not have further follow-up data for a longitudinal evaluation of 
changes in DOC2B. Lastly, the number of adult T1D clinical islet transplantation 
subjects followed was limited by our initial requirement for collection of fresh 
blood for platelet isolation, to be consistent with our pediatric T1D cohort. Given 
our focus on DOC2B as an early predictor of T1D, future studies will examine 
serum and plasma, both of which contain abundant and detectable levels of 
DOC2B. This will permit studies of larger numbers of T1D transplant recipients 
and evaluation of stored samples from a variety of repositories, to enable more 
generalized conclusions. 
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In summary, we demonstrate reduced abundance of the exocytosis protein, 
DOC2B, in prediabetes (NOD mice) or the early onset of T1D (humans). In 
addition, we show a novel correlation between the platelet and islet DOC2B 
levels, suggesting that platelet evaluation may provide prognostic information 
about T1D risk and progression. Furthermore, transplantation of healthy, 
functional islets increased the levels of DOC2B in T1D human platelets. Given 
the need to accurately assess -cell destruction at an early stage, DOC2B may 
be a viable biomarker for T1D. 
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CHAPTER 3 
DOC2B PROTECTS β-CELLS AGAINST INFLAMMATORY DAMAGE AND 
ENHANCES FUNCTION 
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3.1. SYNOPSIS 
Loss of functional -cell mass is an early feature of type 1 diabetes. Functional β-
cells require soluble n-ethylmaleimide-sensitive factor-attachment protein 
receptor (SNARE) complexes to release insulin, as well as SNARE complex 
regulatory proteins like the Double C2-domain protein β (DOC2B). We 
hypothesized that DOC2B deficiency or overabundance may confer susceptibility 
or protection, respectively, to functional β-cell mass. Indeed, Doc2b-/+ 
heterozygous mice show an unusually severe response to multiple low dose 
streptozotocin (MLD-STZ) and have more apoptotic β-cells and less β-cell mass. 
In addition, inducible β-cell specific DOC2B overexpressing transgenic (Doc2b-
dTg) mice resist MLD-STZ-induced β-cell damage, fasting hyperglycemia, and 
impaired glucose tolerance as compared with control MLD-STZ mice; similarly, 
human β-cells overexpressing DOC2B resist cytokine-induced apoptosis. 
Mechanistically, DOC2B enrichment was found to enhance glucose-stimulated 
insulin secretion (GSIS) and SNARE activation. Furthermore, expression of a 
DOC2B peptide, comprised of its tandem C2A and C2B domains, is sufficient to 
confer the GSIS- and SNARE-enhancement effects of full-length DOC2B; 
expression of either C2 domain alone was without benefit. DOC2B and C2AB 
enrichment confer protection from cytokine or thapsigargin-induced -cell 
apoptosis. These studies identify a DOC2B peptide that confers the beneficial 
functional effects of DOC2B and may be a target to protect functional -cell mass.  
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3.2. INTRODUCTION 
In the United States, type 1 diabetes (T1D) currently affects an estimated 1.25 
million people, and this prevalence is predicted to rise to 5 million Americans by 
2050 [162-164]. T1D is characterized by hyperglycemia caused by autoimmune 
destruction of islet β-cells, leading to a decline in β-cell function and mass. 
Increasing evidence shows that β-cell dysfunction precedes clinical onset of type 
1 diabetes [92, 165]. Indeed multiple clinical trials show that T1D patients who 
display even minimal β-cell function at the onset of study exhibit decreased 
microvascular complications, including retinopathy, and neuropathy [166, 167]. 
Currently available therapy for T1D patients is limited to exogenous insulin 
replacement. The danger in this approach, however, is that normal, glucose-
dependent release of endogenous insulin is lost, and that life-threatening 
hypoglycemic episodes and destruction of β-cell mass persists. Thus, there is a 
high demand for alternate/adjuvant therapies that can promote the preservation 
of β-cell mass and function. 
 
Normal insulin secretion is dependent on an intact insulin secretory process 
machinery, termed “SNARE (soluble n-ethylmaleimide-sensitive fusion protein-
attachment protein receptor) proteins”. The SNARE complex consists of two 
target membrane (t)-SNARE proteins, Syntaxin and SNAP25, and one vesicle 
associated (v-SNARE) protein, VAMP [10, 11, 14, 46]. Upon glucose stimulation, 
one v-SNARE binds with two cognate t-SNARE proteins in a 1:1:1 heterotrimeric 
ratio [14]. SNARE proteins facilitate the biphasic manner of insulin secretion 
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using different requisite SNARE protein isoforms [134, 168]. The first phase of 
insulin secretion (first 5-10 minutes following glucose stimulation) uses syntaxin 
1A (STX1A), syntaxin 4 (STX4), SNAP25 or SNAP23, and the v-SNARE VAMP2, 
whereas second-phase (>10 minutes following glucose stimulation) utilizes STX4, 
SNAP25 or SNAP23, and VAMP2 [35, 38, 44, 46, 47, 169, 170]. Another v-
SNARE protein, VAMP8, also functions in insulin secretion but is required 
selectively for glucagon-like peptide (GLP-1) enhanced insulin release [52]. 
 
Assembly of the SNARE complex in the β-cell is regulated by accessory binding 
proteins, such as “SM” (Sec1/Munc18) and DOC2B (double C2-domain 
containing protein). Munc18 proteins localize to the cytosol and plasma 
membrane via direct binding to cognate Syntaxin partner proteins [37, 59, 171]. 
Upon glucose stimulation, Munc18 proteins allow for the “activation” of Syntaxin 
to its VAMP2-accesible “open” conformation, and subsequent assembly of the 
SNARE core complex, and fusion of insulin granules with the plasma membrane 
[26, 56]. DOC2B, via interactions with Munc18 proteins and Syntaxins, is 
essential for this mechanism to occur [56, 60, 74]. 
 
DOC2B belongs to the family of double C2 domain proteins. It is a ubiquitously 
expressed, 46-50 kDa protein, and has been shown to localize to the plasma 
membrane in β-cells and muscle/fat cells [28, 33, 56]. DOC2B is composed of an 
N-terminal Munc13-interacting domain (MID) linked to C-terminal tandem C2 
domains (C2A and C2B), motifs known to bind Ca2+ and phospholipids. The C2A 
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and C2B domains of DOC2B also bind Munc18-1 and Munc18c, respectively, to 
regulate the SNARE complex and facilitate the “activation” of STX4, allowing for 
SNARE complex assembly and subsequent insulin secretion [26-28]. Several 
laboratories have shown that overexpression of DOC2B enhances insulin 
secretion by 30-40% in vitro [28, 60]. Moreover, transgenic mice overexpressing 
DOC2B (simultaneously in the pancreas, skeletal muscle, and adipose tissue) 
show enhanced whole body glucose homeostasis and insulin sensitivity, with 
enhanced islet glucose-stimulated insulin secretion (GSIS) ex vivo, but have 
normal fasting insulinemia [33]. These data suggest DOC2B enrichment to be 
beneficial, although detailed mechanisms for DOC2B actions in the β-cells are 
limited by the use of a global transgene expression system. Doc2b null knockout 
mice harbor dysfunctional islets [24, 25], consistent with observed low DOC2B 
transcript levels in islets of diabetic rodents [135]. However, it remains unknown 
whether DOC2B deficiency is causal or consequential to the loss of β-cell 
function and diabetes onset. 
 
In this study, we tested the hypothesis that DOC2B deficiency underlies β-cell 
dysfunction and susceptibility to diabetes, and that Doc2b enrichment selectively 
in the β-cell is sufficient to confer protection against pro-inflammatory stimuli. 
Data gained from DOC2B heterozygous knock out mice, inducible β-cell specific 
transgenic DOC2B over-expressing (Doc2b-dTg) mice, and DOC2B-boosted 
rodent β-cells, provide strong support for this hypothesis. Furthermore, these 
Doc2b-dTg mice also show enhanced glucose tolerance under standard 
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conditions, associated with a robust capacity for robust insulin release, prompting 
investigations into the molecular mechanism by which DOC2B enrichment boosts 
GSIS. Furthermore, we show that enrichment of a peptide comprised of the 
DOC2B’s tandem C2 domains (C2AB) is sufficient to confer the GSIS boosting 
effect of full-length DOC2B and also confers protection against thapsigargin-
induced β-cell apoptosis. 
 
3.3. RESEARCH DESIGN AND METHODS 
 3.3.1. Materials 
Rabbit anti- DOC2B antibody used for detection of endogenous DOC2B levels 
and detection of h DOC2B -DDK was purchased from Proteintech (1:1000 
dilution, Rosemont, IL, USA, cat# 20574-1-AP). Rabbit anti-cMyc antibody was 
purchased from Santa Cruz Biotechnology (1:1000 dilution, Dallas, TX, USA, 
cat# sc-40). The rabbit anti-STX4 antibody used in the pull-down binding assay 
was generated in-house [172]. Cleaved caspase 3 antibody was purchased from 
Cell Signaling (1:1000 dilution, Danvers, MA, USA, cat# 9661). The CHOP 
antibody used was purchased from Cell Signaling (1:1000 dilution, Danvers,  
MA, USA, cat# 2895). The PARP antibody was purchased from Cell Signaling 
(1:1000 dilution, Danvers, MA, USA, cat# 9532). Phospho-eIf2a and eIf2a 
antibodies were purchased from Cell Signaling (1:1000 dilution, cat#9721 and 
#9722). Tubulin antibody was purchased from Abcam (1:5000 dilution, 
Cambridge, MA, USA, cat#ab56676). Goat anti-rabbit- and anti-mouse-
horseradish peroxidase secondary antibodies were purchased from Bio-Rad 
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(Hercules, CA, USA, cat# 1706515; 1706516). Thapsigargin was purchased from 
Sigma (cat #T9033). Glutathione sepharose 4B agarose beads were obtained 
from GE Life Sciences (Pittsburgh, PA, USA). Enhanced chemiluminescence 
(ECL) was purchased from Amersham Biosciences (Pittsburg, PA, USA). 
Humulin R was obtained from Eli Lilly and Co. (Indianapolis, IN, USA). 
 3.3.2. Animals and in vivo experiments 
Animals were maintained under protocols approved by the Indiana University 
School of Medicine and City of Hope Institutional Animal Care and Use 
Committees and followed the Guidelines for the Use and Care of Laboratory 
Animals. Doc2b-/+ heterozygous mice were generated as described previously 
[24]. Rat Doc2b cDNA was subcloned into the 5’ Pme1 and 3’ BamH1 restriction 
sites in the pTRE-pIRES-eGFP vector (gift from Drs. Solomon Afelik and Jan 
Jenssen, Cleveland Clinic) downstream of the TRE (tetracycline response 
element) to provide tetracycline/doxycycline (Dox) inducibility. Linearized plasmid 
was microinjected into C57BL6 oocytes (Transgenic Core, Indiana University 
School of Medicine). Of two founders, one transmitted the transgene to offspring, 
and was shipped to the City of Hope Animal Research Center for subsequent 
colony expansion. TRE-Doc2b-/+ offspring crossed to rat insulin promoter (RIP)-
rtTA-/+ mice (purchased from Jax Labs) produced Dox-inducible β-cell selective 
expression in the double transgenic offspring (Doc2b-dTg) mice. Mice were 
generated and maintained on the C57BL/6J genetic background. Female 
Doc2b-dTg mice and single transgenic controls were fasted 6 h (08:00-14:00 
hours) before intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal 
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insulin tolerance test (IPITT) analyses as previously described [24]. 2 mg/ml of 
glucose, and 1U/kg insulin were administered to mice for IPGTT and IPITT 
analyses, respectively. Streptozotocin (STZ) was freshly prepared in cold saline 
and injected intraperitoneally in multiple low doses (MLD; 35 mg/kg body weight, 
as described [173]) into male Doc2b-/+ and wildtype littermates (aged 8 weeks) 
for 5 consecutive days and assessed by IPGTT on day 10. Male mice were used 
for STZ experiments as this sex is reportedly more sensitive to STZ treatment, as 
previously described [174]. Male Doc2b-dTg mice (aged 9-10 weeks) were 
provided Dox-treated (2 mg/ml) or standard drinking water for 3 weeks prior to 
MLD-STZ (35-40 mg/kg doses); IPGTT was assessed on day 24. On day 25 
serum samples and tissues were collected, with pancreata fixed and paraffin-
embedded for TUNEL staining. Non-STZ-treated male and female mice were 
used for tissue harvest and evaluation of expression of SNARE and SNARE 
accessory proteins. Serum insulin levels were measured via radioimmunoassay 
(Millipore). 
 3.3.3. Immunofluorescence and cell death assay 
Paraffin-embedded pancreatic tissue sections were prepared and assessed as 
previously described [59]. To assess -cell specificity, pancreatic sections were 
immunostained with guinea pig anti-insulin (1:100 dilution, Dako/Agilent, Santa 
Clara, CA, USA cat#A0564), rabbit anti- DOC2B (1:200 dilution, Proteintech, 
Rosemont, IL, USA, cat# 20574-1-AP), and mouse anti-glucagon (1:200 dilution, 
Santa Cruz Biotechnology, Dallas, TX, USA, cat# sc-13091). Alexa Fluor 555 
goat anti-rabbit, 647 goat anti-guinea pig, and 405 goat anti-mouse IgG (H+L) 
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were used to detect DOC2B, insulin, and glucagon, respectively. To assess 
apoptosis, pancreatic sections were immunostained with guinea pig anti-insulin 
(1:100 dilution, Dako/Agilent, Santa Clara, CA, USA cat#A0564). The TUNEL In 
Situ Cell Death Detection Kit Fluorescein (Roche, Mannheim, Germany) was 
used to stain apoptotic cells. Alexa Fluor 488 goat anti-guinea pig IgG (H+L) 
(1:500 dilution, Invitrogen) secondary antibody was used for detection of insulin. 
Sections were scanned using Zeiss Axio Observer and LSM 700 microscopes 
and analyzed using Image-Pro Software (Media Cybernetics, Rockville, MD, 
USA). Results were expressed as the percentage of cells positive for TUNEL 
staining relative to the total number of insulin-positive cells. 
 3.3.4. Cell culture, transfections, GSIS and binding assays 
Human DOC2B adenovirus was generated by insertion of the hDoc2b-mycDDK 
cDNA from the pCMVhDoc2bmycDDK plasmid (purchased from OriGene 
Technology, Inc. MD, USA) into the pAd5CMVmpA adenoviral vector. 
Adenoviruses were packaged with EGFP to enable visualization of infection 
efficiency, amplified, and purified for use by Viraquest, Inc. (North Liberty, IA, 
USA). Rat INS-1 832/13 β-cells (gift from C.B. Newgard, Duke University, 
Durham, NC, USA and Patrick Fueger, City of Hope, Duarte, CA, USA) were 
cultured in RPMI 1640 medium as previously described [175] and transduced 
with Ad5-CMV-human (h)Doc2b prior to treatment with a cytokine mixture (10 
ng/ml TNF-, 100 ng/ml IFN- and 5 ng/ml IL-1; ProSpec, East Brunswick, NJ, 
USA) for 16 h, as previously described [151]. Cells were harvested in 1% NP-40 
lysis buffer and cleared detergent lysates were used for immunoblotting for 
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apoptosis/ER stress markers. Mouse MIN6 β-cells were cultured as described 
[55]. Cells were pre-incubated in serum-free media for 2 h followed before cells 
were harvested in 1% NP-40 lysis buffer and cleared detergent lysates were 
used for glutathione S transferase (GST)-VAMP2 interaction assays, as 
described previously [172]. Rat INS-1 832/13 β-cells (passage 70-80) and MIN6 
β-cells (passage 3-7) were used for GSIS analyses performed using the K2 
Transfection System (Biontex, Munchen, Germany). Doc2b-GFP and C2AB-GFP 
(gift from U. Ashrey, Tel-Aviv University, Ramat-Aviv, Israel).GSIS analyses were 
performed as previously described. INS-1 832/13 cells were placed in low 
glucose/low serum medium overnight prior to starvation in KRBB for 1 hr and 
glucose treatment (basal, 2.8 mM or glucose stimulated, 20 mM) for 30 minutes. 
MIN6 cells were starved in MKRBB for 1 hr prior to glucose treatment (basal-2.8 
mM or glucose stimulated-20 mM). Supernatants were collected for insulin levels 
to be analyzed using the Rat Insulin ELISA (Mercodia, Uppsala, Sweden) or 
mouse Insulin ELISA (Alpco, Salem, NH, USA), respectively. 
 3.3.5. Islet Morphometry 
Islet morphometry was evaluated using anti-insulin immunohistochemical stained 
pancreatic sections as described [151]. Percentage of β-cell area was calculated 
using Keyence BZX-Analyzer software (Keyence Corporation, Itasca, IL, USA). 
Data shown are representative of three pancreatic sections per mouse. β-cell 
mass was calculated by multiplying percentage of β-cell area with pancreas 
weight. 
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3.3.6. Statistical analysis  
All data are expressed as the mean ± SD for all figures except those 
representing IPGTT/ITT or Area under the curve (mean ± SEM). Data were 
evaluated for statistical significance using Student’s t test for comparison of two 
groups, or ANOVA and Tukey’s posthoc test (GraphPad Software, La Jolla, CA, 
USA) for more than two groups. 
 
3.4. RESULTS 
3.4.1. DOC2B-/+ deficient mice are highly susceptible to STZ-induced 
glucose intolerance 
To assess whether DOC2B abundance impacts β-cell susceptibility to T1D 
insults, we performed IPGTT assays prior to- and following a multiple low dose 
streptozotocin (35 mg/kg body weight) protocol (MLD-STZ), as previously 
described [173]. Prior to MLD-STZ treatment, young 7 wk old male Doc2b-/+ and 
littermate wildtype (Wt) mice showed no differences in blood glucose levels 
(Figure 3.1.A-B). Ten days after the first STZ injection, Doc2b-/+ mice showed 
significantly higher blood glucose levels than Wt mice (Figure 3.1.C-D). One day 
later all pancreata were collected and processed for TUNEL staining, which 
showed Doc2b-/+ mice to have >3-fold higher levels of β-cell apoptosis as 
compared to Wt mice (Figure 3.1.E). Although the number of islets was similar in 
Doc2b-/+ and Wt mice, the percentage of β-cell area was decreased in the Doc2b-
/+ mice, which also resulted in lower β-cell mass (Figure 3.1.F-G). DOC2B levels 
were ~50% reduced in islets from Doc2b -/+ mice (Figure 3.2.A) and before STZ 
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treatment, β-cell mass was similar in Doc2b-/+ vs Wt mice (Figure 3.2.B). Body 
weights of Doc2b-/+ mice were equivalent to those of Wt mice over a 7- to 9-week 
period (Table 3.1.).  
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Figure 3.1. DOC2B-/+ deficient mice are more susceptible to STZ-induced 
glucose intolerance and β-cell apoptosis. A) Prior to treatment with STZ, young 
8 wk old male Wild type (Wt) and DOC2B-/+ mice were fasted 6 h and subjected to 
intraperitoneal glucose tolerance test (IPGTT); n=13 mice/group. B) Quantification of 
area under the curve (AUC) for Pre-STZ IPGTT. C) DOC2B -/+ and wild type 
littermates were then injected daily days 0-5 with STZ (35 mg/kg BW), and on day 
10 were fasted 6 h and subjected to IPGTT; n=8 mice/group. D) Quantification of 
AUC for Post-STZ IPGTT. E) TUNEL immunofluorescent staining and quantification 
of TUNEL-positive β-cells (indicated by arrows in images, expressed as % of total β-
cells) were conducted on fixed pancreases of STZ-treated DOC2B -/+ and Wt mice. 
Data represent mean ± SD; n=5 mice/group. Bar=20 µm. F) Islet β-cell area and G) 
islet β-cell mass were calculated from fixed DOC2B -/+ and Wt pancreases 
immunostained for insulin content; Data represent mean ± SD; n=3 mice/group, 3 
sections/mouse. *p<0.05, **p<0.01, ***p<0.001 DOC2B -/+ vs. Wt mice. 
 87 
 
 
Figure 3.2. Islets from Doc2b -/+ mice are reduced in DOC2B, but have similar 
beta cell mass prior to STZ treatment. (A) Islets from Doc2b-/+ and Wt mice were 
harvested at 7 weeks of age and prepared for SDS-PAGE and immunoblotting with 
DOC2B and Tubulin. N=3 per group, *p<0.05. (B) Pancreata from 7 week old 
Doc2b-/+ and Wt were fixed in 4% paraformaldehyde prior to tissue sectioning and 
staining via immunohistochemistry for assessment of beta cell mass. N=3 per group, 
*p<0.05. 
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Body Weight (g) Wild-type Doc2b -/+ 
Pre-STZ 22.8  0.7 23.8  0.6 
Post-STZ 24.4  0.4 24.2  0.7 
 
 
Table 3.1. Body weights of Wild-type and Doc2b -/+ mice. Data represent the 
average  S.E. Body weights were measured for Wild-type and Doc2b -/+ male 
littermate mice Pre-STZ treatment at 7 weeks of age and Post-STZ treatment at 
9 weeks of age (n=5 for WT and Doc2b +/- ) for determination of parameters 
shown. No statistical differences were seen.  
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3.4.2. Enhanced glucose tolerance in doxycycline-inducible β-cell 
specific DOC2B overexpressing transgenic mice 
To determine whether β-cell specific overexpression of DOC2B is sufficient to 
enhance whole-body glucose tolerance, we generated a doxycycline-induced, β-
cell specific double transgenic mouse model (βDoc2b-dTg) (Figure 3.3.A). 
Doc2b-myc mRNA abundance in islets isolated from female mice was ~4-5-fold 
higher in Dox-induced βDoc2b-dTg mice as compared with non-Dox treated 
βDoc2b-dTg control mice (Figure 3.3.B), and the presence of the myc-tagged 
DOC2B protein was clearly detectable (Figure 3.3.C). No transgene 
overexpression was detected in hypothalamus or cerebellum (Figure 3.3.D). 
Immunofluorescent analysis of βDoc2b-dTg islets show β-cell specific 
overexpression of DOC2B compared with levels in non-Dox treated βDoc2b-dTg 
mice (Figure 3.3.E). 
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Figure 3.3. Generation of β-cell specific Dox-inducible DOC2B-
overexpressing mice. A) Schematic design of RIP-rtTA-/+ mice crossed to new 
TRE-Doc2b -/+ mice. B) Doc2b mRNA, in primary islets isolated from female double 
transgenic (βDoc2b -dTg) mice. C) Dox-induced expression of DOC2B-myc protein 
in isolated islets, and D) lack of overexpression of rDoc2b mRNA in hypothalamus 
or cerebellum of the βDoc2b -dTg mice. E) Immunofluorescent imaging of DOC2B 
overexpression in the islets of the βDoc2b -dTg mice induced with or without Dox. 
Each panel of data represent the mean ± SD of at least three mice per group; 
**p<0.01 βDoc2b -dTg + Dox vs –Dox treated mice. Bar=20 µm.  
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Changes to whole body glucose homeostasis were assessed by IPGTT in 
the βDoc2b-dTg mice. Dox-induced dTg mice showed significantly lower blood 
glucose levels at all time points after glucose injection; basal fasting blood 
glucose levels were comparable to that of non-Dox treated dTg control mice 
(Figure 3.4.A-B) or single transgenic mice (Figure 3.5.). Consistent with this, 
serum insulin levels in Dox-treated βDoc2b-dTg mice were 34% higher than 
controls within the first 10 min of glucose injection during IPGTT, but not 
statistically different under basal (time 0 in the IPGTT) conditions (Figure 3.4.C). 
No differences were seen between Dox-treated or control βDoc2b-dTg mice in 
intraperitoneal insulin tolerance tests, suggesting no changes to peripheral 
insulin sensitivity (Figure 3.4.D-E). No significant differences were seen in 
body/tissue weights of double and  single transgenic mice (Table 3.These data 
suggest that enrichment of DOC2B selectively in adult pancreatic islet β-cells is 
sufficient to improve whole body glucose homeostasis. 
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Figure 3.4. β-cell specific Dox-inducible DOC2B-overexpressing mice have 
enhanced glucose tolerance and glucose-stimulated serum insulin content. 
A) Female βDoc2b-dTg mice at 12-13 weeks of age were fasted 6 h and subjected 
to an intraperitoneal glucose tolerance test (IPGTT); n=5 mice/group. B) 
Quantification of area under the curve (AUC) for IPGTT. C) Serum insulin content in 
mice fasted for 6 h (0 min) and 10 min after a glucose injection. Data shown as 
mean  SD for three to five sets of mice. *p<0.05, **p<0.01 βDoc2b-dTg +Dox vs – 
Dox treated mice. D) Female βDoc2b-dTg mice were fasted 6 h and subjected to an 
intraperitoneal insulin tolerance test (IPITT); n=4 -Dox, n=3 +Dox treated βDoc2b-
dTg mice. E) Area over the curve analyses of the IPITT. *p<0.05 βDoc2b-dTg +Dox 
vs –Dox treated mice.   
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Figure 3.5. β-cell specific Dox-inducible DOC2B-overexpressing mice have 
enhanced glucose tolerance versus single transgenic mice. IPGTT following 
a 6 h fast for female βDoc2b-dTg (TRE-Doc2b; RIP-rtTA) and single transgenic 
controls (TRE-Doc2b/+; RIP-rtTA/+) with and without Dox treatment. Data shown 
are representative of three mice per group, average ±  SEM.  
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 Dox (-) RIP-
rtTA/+ 
  
Dox (+) 
RIP-
rtTA/+ 
  
Dox (-) 
TRE-
Doc2b/+ 
  
Dox (+) 
TRE-
Doc2b/+ 
  
Dox (-) 
TRE-
Doc2b;RIP-
rtTA 
  
Dox (+) 
TRE-
Doc2b; 
RIP-rtTA 
  
Body weight 
(g) 
23.90.90  23.00.83  24.00.90 24.21.10 23.60.60 23.90.20 
Heart (g) 0.090.03 0.170.08 0.250.01 0.100.02 0.140.01 0.110.03 
Liver (g) 1.190.11 1.180.14 1.480.10 1.190.10 1.170.06 1.290.09 
Spleen (g) 0.070.01 0.080.03 0.070.05 0.070.01 0.060.02 0.050.01 
Brain (g) 0.370.03 0.430.04 0.560.01 0.400.02 0.400.02 0.380.02 
Hypothalamus 
(g) 
0.050.02 0.040.02 0.080.03 0.040.01 0.070.04 0.030.01 
Fat (g) 0.380.17 0.320.08 0.370.02 0.290.02 0.340.10 0.220.10 
Muscle (g) 0.270.01 0.270.01 0.250.03 0.220.01 0.210.01 0.200.01 
Tissues (% of body weight) 
Heart (%) 0.380.13 0.740.35 1.040.04 0.410.08 0.590.04 0.460.13 
Liver (%) 4.970.46 5.130.61 6.160.41 4.920.41 4.950.25 5.390.38 
Spleen (%) 0.290.04 0.350.13 0.300.20 0.290.04 0.250.08 0.210.04 
Brain (%) 1.540.08 1.860.17 2.330.04 1.650.08 1.690.08 1.580.08 
Hypothalamus 
(%) 
0.210.08 0.170.08 0.330.13 0.170.04 0.300.17 0.130.04 
Fat (%) 1.580.71 1.390.35 1.540.08 1.200.08 1.440.42 0.920.41 
Muscle (%) 1.120.04 1.170.04 1.450.13 0.910.04 0.890.04 0.840.04 
Table 3.2. Body/tissue weights of Transgenic mice. Data represent the 
average  S.E. Body and tissue weights were measured for Dox (-) RIP-RtTA/+, 
Dox (+) RIP-rtTA/+, Dox (-) TRE-Doc2b/+, Dox (+) TRE-Doc2b/+, Dox (-) TRE-
Doc2b;RIP-rtTA, and Dox (+) TRE-Doc2b; RIP-rtTA female littermate mice at 15-
18 weeks of age (n=3 for each group) for determination of parameters shown. No 
statistical differences were seen. 
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3.4.3. Doc2b-dTg mice are protected from STZ-induced glucose 
intolerance and β-cell apoptosis. 
Male βDoc2b-dTg mice were subjected to the MLD-STZ protocol to determine if 
DOC2B enrichment in the β-cell provides protection from T1D-simulated 
destruction. IPGTT assessments at 24 days post-initiation of the protocol (14 
days longer than used with Doc2b-/+ mice) induced substantially increased blood 
glucose levels, with fasting levels ~300 mg/dl in non-dox-treated dTg mice 
(Figure 3.6.A-B). In contrast, Dox-induced βDoc2b-dTg mice were largely 
protected, even with the extended time after STZ treatment for maximal 
destruction.  
 
To determine if protection from STZ-induced glucose intolerance and fasting 
hyperglycemia in the βDoc2b-dTg mice was related to changes in β-cell 
apoptosis, pancreata from the STZ-treated dTg mice were assessed by TUNEL 
staining. Islets from Dox-treated βDoc2b-dTg mice had ~58% fewer apoptotic 
cells than non-Dox-treated dTg mice (Figure 3.6.C). Dox-treated βDoc2b-dTg 
mice had higher β-cell area, corresponding to increased β-cell mass, compared 
with non-dox treated dTg mice (Figure 3.6.D-E). Additionally, GLUT2 expression 
was unchanged in Dox+ and Dox- dTg mice (Figure 3.7). Body weights of dTg -/+ 
Dox were similar pre and post-STZ treatment (Table 3.3.). These data suggest 
that overexpression of DOC2B protects islet β-cells against STZ-induced β-cell 
death. 
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Figure 3.6. β-cell specific Dox-inducible DOC2B-overexpressing mice are 
protected from STZ-induced glucose intolerance, fasting hyperglycemia, 
and β-cell apoptosis. A) Male βDOC2B-dTg mice aged 12-13 weeks old were 
injected daily on days 0-5 with STZ (35-40 mg/kg body weight), and on day 24 were 
fasted 6 h and subjected to an IPGTT, also shown: AUC quantification for IPGTT; 
n=3 –Dox, n=5 +Dox βDOC2B-dTg mice. B) Fasting blood glucose of STZ-treated 
βDOC2B-dTg mice; data represent mean ± SD; n=3 –Dox, n=5 +Dox βDOC2B-dTg 
mice. C) Immunofluorescent staining and quantification of TUNEL-positive β-cells 
(indicated by arrows in images, expressed as % of total β-cells) were conducted on 
fixed pancreases of –Dox and +Dox-treated βDOC2B-dTg mice; data represents 
mean ± SD; n=3 –Dox, n=5 +Dox. Bar=20 µm. D) Islet β-cell area and E) islet β-cell 
mass were calculated from fixed βDOC2B-dTg whole pancreases immunostained 
for insulin content. Dotted line indicates the β-cell area and mass of non-STZ treated 
wild type mice in our colony [151]; Data represent mean ± SD; n=3 mice/group, 3 
sections/mouse. *p<0.05, **p<0.01 βDOC2B-dTg +Dox vs – Dox treated mice. 
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Figure 3.7. GLUT2 levels are unchanged in Dox- and Dox+ dTg mice. Islets 
from 12 week old female Dox- and Dox+ Doc2b-dTg mice were harvested and 
prepared for SDS-PAGE and immunoblotting for the -cell specific glucose 
transporter, GLUT2. N=3, *p<0.05.  
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Body Weight (g) dTg - Dox dTg + Dox 
Pre-STZ 27.3  1.2 29.4  0.9 
Post-STZ 28.3  0.7 29.4  1.1 
 
Table 3.3. Body weights of dTg-Dox and dTg+Dox mice, Pre/Post-STZ. Data 
represent the average  S.E. Body weights were measured for dTg-Dox and 
dTg+Dox male littermate mice Pre-STZ treatment at 12-13 weeks of age and 
Post-STZ treatment at 15-16 weeks of age (n=3 for dTg-Dox and N=5 for 
dTg+Dox ) for determination of parameters shown. No statistical differences were 
seen. 
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 3.4.4. Doc2b overexpression protects against cytokine-induced 
 apoptosis and reduces ER stress. 
To date all studies of DOC2B overexpression in islet and in vivo function have 
used rat DOC2B; human (h) DOC2B has yet to be tested. Toward this, we 
generated adenoviral particles encoding hDoc2b tagged C-terminally with FLAG-
DDK. Ad-hDoc2b-DDK was packaged with GFP for detection of 70% of rat INS-
1 832/13 cells being virally-transduced (Figure 3.8.A). Treatment of Ad-hDOC2B-
expressing INS-1 832/13 cells with pro-inflammatory cytokines for 16 h resulted 
in a 45% reduction in cleaved caspase-3 (CC3) and >50% reduction in cleaved 
PARP as compared with Ad-control (Cntl) treated cells (Figure 3.8.B). 
Additionally, levels of ER stress markers, CHOP and Phospho-eIF2a were 
reduced by ~50% and ~60%, respectively, in Doc2b overexpressing β-cells 
(Figure 3.8.B). These data confirm that Doc2b promotes protection from 
apoptotic stimuli and reduces ER stress. 
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Figure 3.8. DOC2B-overexpression in rat INS-1 832/13 cells cells protects 
against pro-inflammatory cytokine-induced β-cell apoptosis and ER stress. 
A) Rat INS-1 832/13 were transduced with Ad5-CMV-hDOC2B-DDK or control virus 
(Cntl, Ad5-CMV) and subsequently treated with a cocktail of pro-inflammatory 
cytokines (10 ng/ml TNF-, 100 ng/ml IFN- and 5 ng/ml IL-1). B) Cleared 
detergent cell lysates were assessed for hDOC2B-DDK (~51 kDa, endogenous is 
46 kDa) overexpression and effect upon cleaved caspase-3 (CC-3) levels. Asterisk 
indicates phospho-eIF2a band used for analysis. Tubulin and GFP served as 
controls for protein loading and cell line transduction, respectively. Vertical dashed 
line indicates splicing of a lane from within the same gel exposure. Data represent 
the mean ± SD of three independent sets of homogenates for each cell line; *p<0.05, 
***p<0.001 for Ad-CMV-DOC2B vs Ad-CMV-Cntl treated cells. Bar=400 µm. 
 
  
* 
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3.4.5. A Doc2b peptide (C2AB) is sufficient to protect against 
thapsigargin-induced ER stress via calcium coordination. 
The DOC2B protein is composed of three primary domains, MID, C2A and C2B 
(Figure 3.9.A); the C2 domains are known calcium-sensing domains, binding 2 
calcium ions each, and contributing to DOC2B’s function. To further investigate 
DOC2B’s anti-apoptotic actions and the role of C2 tandem domains in alleviating 
ER stress, plasmids encoding rDOC2B and an N-terminal truncation of the MID 
domain (referred to as C2AB), and a calcium ligand mutant form of C2AB 
(CaMut), which harbors 4 aspartic acid residue mutations (D218N, D220N, 
D357N, D359N), all with C-terminal GFP tags were generated (Figure 3.9.A). 
INS-1 832/13 cells were treated with a commercially available ER stress inducer 
and SERCA2b pump inhibitor, Thapsigargin. Treatment of DOC2B-GFP and 
C2AB-GFP overexpressing INS-1 832/13 cells with 1M Thapsigargin for 6 h 
resulted in decreased levels of CHOP and CC3 compared to control (GFP) 
treated cells (Figure 3.9.B). These levels were similar to levels of CHOP and 
CC3 in cells treated with the calcium chelator, EGTA (Figure 3.9.B). This effect 
was abolished when cells were transfected with CaMut, as levels of CHOP and 
CC3 were elevated close to that seen in  control (GFP) transfected cells (Figure 
3.9.B). These data suggest that Doc2b’s calcium binding capacity within the 
C2AB tandem domains is responsible for its protective effect against ER stress 
and apoptosis. 
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Figure 3.9. C2AB is sufficient to protect against thapsigargin-induced ER 
stress via calcium coordination. Rat INS-1 832/13 cells were transfected with 
rDoc2b, rC2AB, or CaMut (calcium ligand mutant of C2AB), and treated with 
Thapsigargin (1uM) for 6 hr prior to harvest with 1% NP40 lysis buffer. EGTA was 
used as a calcium chelator negative control. Whole cell lysates were run on SDS-
PAGE  gel for immunoblotting and assessed for levels of CHOP and CC3 proteins. 
Data represents average of independent 3 sets, *p<0.05. 
 
  
A) 
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3.4.6. DOC2B peptide C2AB is sufficient to enhance insulin 
exocytosis. 
The C2AB peptide was sufficient to protect β-cell against thapsigargin-induced 
apoptosis; we also wanted to investigate the capacity of C2AB and individual C2 
domains (C2A and C2B) (Figure 3.10.A) to recapitulate DOC2B’s functional 
enhancing properties. Full length rDOC2B-GFP expression in MIN6 cells 
recapitulated the enhancement of GSIS seen with rDOC2B in prior reports [28, 
33, 60]. Remarkably, C2AB enhanced GSIS by the same ~2-3-fold level as did 
full length DOC2B (Figure 3.10.B). Neither C2A or C2B expression individually 
resulted in enhanced GSIS, despite confirmed expression of each to levels 
comparable to DOC2B-GFP; if anything, C2AB-GFP expression levels were 
slightly lower than the other proteins (Figure 3.10.C). Insulin content was also 
similar amongst all treatment groups (Figure 3.11A.). These results were 
recapitulated when constructs were tested in INS-1 832/13 cells (Figure 3.10.D-E, 
and Figure 3.11B.). DOC2B has been shown to be required for SNARE complex 
formation in β-cells, possibly via increasing STX4 activation and interaction with 
its cognate v-SNARE partner VAMP2 [33]. To determine if C2AB carries the 
capacity to replicate the underlying mechanism, C2AB or DOC2B proteins 
(untagged) were tested for the ability to evoke an increase in STX4 binding to 
GST-VAMP2 (Figure 3.10.F). Notably, C2AB protein fully recapitulated this 
increase in STX4 activation. These data suggest that C2AB constitutes a minimal 
region of DOC2B that is sufficient to confer enhanced GSIS and STX4 activation.  
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Figure 3.10. Ability of the N-terminal truncation product C2AB to mimic full-
length DOC2B function in glucose-stimulated insulin secretion. A) 
Schematic of the rDOC2B-GFP truncation constructs. B) GSIS in MIN6 cells 
expressing full length rDOC2B, the N-terminal truncation mutant C2AB, and 
individual C2A or C2B domains. C) Expression was confirmed by immunoblotting; 
asterisks denote presence of the C2A, C2B, and C2AB bands by their expected 
molecular weights. Vertical dashed line indicates splicing of lanes from within the 
same gel exposure. D-E) GSIS and protein expression of rDOC2B-GFP truncation 
mutants in INS-1 832/13 cells; asterisks denote C2A, C2B, and C2AB bands. F) 
C2AB mimics the enhancement effect of full length DOC2B upon STX4 activation in 
MIN6 cells. Data represent the mean ± SD of three independent sets of 
homogenates. *p<0.05 DOC2B or C2AB vs. GFP. 
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Figure 3.11. Insulin content is similar in all transfected groups. A) Insulin 
content/mg protein for MIN6 and B) INS-1 832/13 transfected cells with full length 
or C2 domains. Data shown are representative of three to four independent sets 
of tissue homogenates, average ± SEM. No significant differences were detected. 
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3.5 DISCUSSION 
The data presented here demonstrate an important role for DOC2B in 
maintaining β-cell mass and function. We propose that Doc2b deficiency leaves 
β-cells more susceptible to diabetogenic damage, and that overexpression of 
DOC2B in the β-cell enhances whole body glucose homeostasis and protects β-
cell mass in an anti-apoptotic manner. We also show that C2AB comprises a 
minimal Doc2b peptide that is required for enhanced insulin secretion, and that 
its anti-apoptotic effects may involve calcium coordination within the C2AB 
peptide. Hence, the C2AB may provide a new target for promoting and protecting 
functional β-cell mass. 
 
To our knowledge, this study is the first report of DOC2B having protective, anti-
diabetic properties. Data presented herein reveals that Doc2b deficient mice (-/+) 
show greater susceptibility to MDL-STZ-induced β-cell destruction and worsened 
glucose tolerance. Contrasting this, our β-cell specific double transgenic DOC2B 
mice show enhanced whole-body glucose tolerance and resist MLD-STZ-induced 
glucose intolerance. TUNEL analyses and islet morphometry show the DOC2B-
overexpressing mice have protected β-cell mass. INS-1 832/13 β-cells 
transduced to overexpress human DOC2B also exhibit protection from pro-
inflammatory cytokine and thapsigargin-induced apoptosis, indicating that 
DOC2B protection occurs at the level of the β-cells, and the protective effect is 
not dependent upon inter-islet non-β-cell communication nor due to a circulating 
factor in vivo. The role of DOC2B or other exocytosis proteins in β-cell survival 
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mechanisms still remains largely unexplored, however recent reports have 
shown involvement of exocytosis proteins, such as VAMP8 involved in regulating 
β-cell proliferative events [52]. In neurons, DOC2B has been implicated in 
proliferation and differentiation during early embryogenesis [105, 106]. Yet, islet 
mass by morphometry in mouse islets with increased or decreased DOC2B 
levels isolated from mice under standard conditions, unchallenged by 
diabetogenic stimuli, is reportedly unchanged from that of wild-type littermate 
mice [24, 25, 33]; these data do not support the concept that DOC2B 
overexpression is acting via promoting proliferation or differentiation in the β-cell 
per se. Data reported here point to the action of DOC2B overexpression in 
promoting β-cell survival and protecting β-cell mass in the face of inflammatory 
and ER stress, with the protection occurring at the level of the β-cell itself. This is 
supported by our data showing the anti-apoptotic actions of h DOC2B 
overexpression in rat β-cell lines.  
 
DOC2B is a C2-domain containing protein, in the family of proteins including 
Munc13, synaptotagmins, Ferlins, Rabphilin 3A and RIM1/2 [176-178]. These 
proteins have in common two aspects: all are calcium regulated/calcium sensing, 
and all are implicated in vesicle trafficking/exocytosis. The role of DOC2B as a 
calcium sensor in β-cells has been reported [60] and the tandem C2 domain 
region of DOC2B, referred to here as the C2AB, has been shown to be sufficient 
to support membrane fusion in cell-free assays, and shows stronger liposome 
binding than either of the isolated C2A and C2B domains [106]. Indeed, our data 
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show that C2AB can fully recapitulate the anti-apoptotic effects of full-length 
DOC2B in a calcium coordinating fashion. The calcium mutant form of C2AB has 
been previously reported to abolish DOC2B’s calcium binding capacity [179]. ER 
stress mechanisms are known to be calcium-dependent events, and thus we 
propose that DOC2B overexpression may lead to sequestration of calcium ions, 
resulting in reduced cleaved caspase 3, PARP, CHOP and P-eIF2a.  
 
C2AB also recapitulated GSIS enhancement seen with full-length DOC2B, 
whereas the C2 domains individually did not. Interestingly, the C2AB protein was 
able to recapitulate the activating effect of full-length DOC2B upon STX4 
activation, consistent with prior work showing DOC2B to promote SNARE protein 
assembly [26, 60, 73, 74]. C2AB may confer its SNARE complex- promoting 
effect, in part, by acting directly on the membrane, as recent work shows that 
C2AB is sufficient to assemble in a ring-like oligomer [180], and act directly on 
membranes in regulating hemifusion events in neurons [181]. These findings are 
important starting points for further mechanistic investigation of DOC2B function 
in β-cells. 
 
In summary, the data presented here show a novel, anti-apoptotic role for 
DOC2B in the β-cell. We propose that overexpression of DOC2B is sufficient to 
enhance whole body glucose homeostasis, and to protect β-cell mass against 
T1D-related stress. Furthermore, we show that the tandem C2AB domain is 
sufficient to enhance insulin secretion and protect against apoptosis, and that this 
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may be due to calcium coordination. DOC2B thus carries the potential to be a 
therapeutic target for prevention/management of T1D. 
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CHAPTER 4 
DISCUSSION 
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4.1. OVERVIEW 
The objective of my dissertation was to investigate whether DOC2B abundance 
was compromised during the development of T1D, and whether early, β-cell 
specific enrichment of DOC2B would protect functional beta cell mass against 
T1D insults. Toward this, DOC2B protein abundance was assessed in islets and 
blood borne platelets of new-onset T1D rodents and humans, as well as in the 
platelets of T1D islet transplant recipients. Additionally, β-cell specific transgenic 
mice were used to investigate the effect of DOC2B overexpression on whole 
body glucose homeostasis and β-cell mass under diabetogenic conditions. In the 
following sections, I will highlight findings from each chapter and future studies 
necessary to further elucidate the mechanisms of the phenomena described 
herein. Finally, I will discuss the overall significance and translational potential of 
the current studies in the context of preventing/treating T1D. 
 4.1.1. Major findings 
DOC2B is one of three isoforms (α, β, and γ) belonging to the family of Double 
C2 domain proteins, and is known to regulate SNARE-mediated secretion both in 
neurons and β-cells. Previously, our laboratory and others have demonstrated 
that DOC2B overexpression enhances GSIS in vitro, and in vivo via a whole 
body transgenic model [28, 33]. My studies validate these findings, and 
furthermore, establish a correlation between T1D and DOC2B abundance in 
islets and platelets. My studies also provide evidence that DOC2B 
overexpression protects β-cell mass against T1D insults. In addition to 
establishing a correlation between T1D and DOC2B, the following major findings 
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were resultant of the current study: 1) DOC2B abundance is reduced in platelets 
of non-obese diabetic mice before conversion to T1D, and this reduction was 
mirrored in islets of the same mice; 2) DOC2B abundance is reduced in platelets 
of new-onset T1D human subjects, as well as in islets of early-onset T1D 
humans and islets treated with pro-inflammatory cytokines in vitro; 3) β-cell 
specific overexpression of DOC2B results in enhanced whole body glucose 
homeostasis in the absence and presence of T1D diabetogenic stress; 4) 
DOC2B overexpression protects β-cell mass against T1D diabetogenic stress in 
an anti-apoptotic manner; 5) the truncated C2AB domain recapitulates enhanced 
GSIS, STX4 activation, and mutations of DOC2B residues implicated in calcium 
handling ablate the functional and protection action of DOC2B and C2AB, 
respectively. 
4.1.2. DOC2B abundance is reduced in platelets and islets from 
prediabetic rodents and new onset T1D human subjects; DOC2B 
abundance is restored after clinical islet transplantation. 
My studies aimed to investigate whether DOC2B was a viable biomarker of β-cell 
destruction in T1D. Platelets were used as a blood-borne source of biomarkers 
because they harbor many of the same exocytosis proteins as the pancreatic β-
cell, including DOC2B, and changes in platelet proteome and morphology have 
been noted in T1D [146]. My data established that prior to onset of T1D, and 
while still exhibiting normoglycemia, NOD mice have reduced abundance of 
DOC2B in platelets, and this reduction is mirrored in NOD islets versus NOR 
control mice, even as early as 7 weeks of age. I next sought to investigate 
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whether reduced platelet DOC2B levels was translatable in humans. My research 
revealed that DOC2B protein levels are reduced in platelets of new-onset T1D 
subjects, and remain low 7-10 weeks post-diagnosis, despite therapeutic 
intervention and remediation of hyperglycemia. DOC2B abundance is also 
reduced in cadaveric T1D human islets compared to non-diabetic controls. In 
vitro, treatment of non-diabetic human islets with pro-inflammatory cytokines 
results in decreased DOC2B protein and mRNA abundance, suggesting that the 
inflammatory milieu is causal to DOC2B loss. Remarkably, within 30 days of islet 
transplantation in T1D subjects, robust increase in DOC2B protein is evident, and 
persisted to the 75-day sampling. Increases in platelet DOC2B levels coincided 
with increased plasma C-peptide levels in both transplant subjects, suggesting 
that increased platelet DOC2B levels mirror increased infused functional islet 
mass.  
 
To our knowledge, this is the first study to establish an association between T1D 
and levels of an exocytosis protein in blood-derived platelets and pancreatic 
islets. Reduced DOC2B in islets is indicative of deficient islet functional health 
[24]. Strikingly, platelet DOC2B levels in islet transplant recipients correlated with 
the presence of a functional islet mass. This correlative finding supports the 
possibility that the platelet DOC2B stems not necessarily from the pancreas per 
se, since islets are grafted into the liver in these human recipients, but that the 
platelets and/or precursor megakaryocytes may be sampling DOC2B from the 
islets irrespective of islet location. It also remains possible that the increased 
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DOC2B content stems from ‘rested’ native residual islets of the transplanted 
patients. However, this is inconsistent with our pediatric platelet data showing 
that even after insulin therapy to ameliorate new-onset hyperglycemia, DOC2B 
levels remained deficient. Mechanistically, questions arise as to if and how 
platelets and islets communicate to determine DOC2B levels. Supporting the 
concept of platelet-islet communication, it has been demonstrated that islet 
transplantation in T1D patients stabilizes platelet abnormalities, as transplant 
recipient platelets show normal volume and activation [155]. Indeed, -cells 
release exosomes as a way of shuttling various miRNAs, mRNAs, and proteins 
to targeted peripheral cells [156]. -cell exosomes were also recently shown to 
carry proteins, such as GAD-65, IA-2, and proinsulin, to dendritic cells, which 
then become activated [157]. Could islets similarly release DOC2B mRNA or 
protein, which is subsequently taken up by megakaryocytes or by the platelets 
themselves? Furthermore, platelets can selectively absorb proteins from the 
blood [158]. In fact, platelet sequestration of tumor-specific proteins was detected 
in animals harboring small tumors [158]. Notably, a direct interaction between 
platelets and pancreatic β-cells has been reported, and protein from platelets 
was shown to be transferred to β-cells [159]. Is it possible that the platelets are 
sampling the islets to mirror islet DOC2B levels? Previously, our lab and others 
established that reduced levels of DOC2B proteins in islets is indicative of 
deficient islet functional health overall [24, 25]. Thus, reduced levels of DOC2B in 
blood-borne platelets may mirror reduced functional β-cell mass.  
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4.1.3. DOC2B deficiency increases susceptibility to T1D insults; 
DOC2B overexpression protects beta cell mass in an anti-apoptotic 
manner.  
DOC2B deficiency renders pancreatic islets dysfunctional [24, 25]. Additionally, 
low DOC2B transcript levels have been reported in islets of diabetic rodents [135]. 
Thus, my studies aimed to investigate the hypothesis that DOC2B deficiency 
underlies β-cell dysfunction and susceptibility to diabetes. My research revealed 
that following multiple low dose STZ treatment, DOC2B heterozygous (-/+) mice 
show worsened glucose tolerance compared to wild type littermate control mice. 
Isolated pancreata from MLD-STZ treated DOC2B-/+ mice show ~3 fold higher 
levels of β-cell apoptosis, which corresponded with lower β-cell mass than Wt 
control mice.  
 
Given that DOC2B deficiency increases susceptibility to T1D damage, my 
research next aimed to investigate whether overexpression of DOC2B had a 
protective effect on β-cell mass under the same diabetogenic conditions. Thus, 
we generated a doxycycline-inducible, β-cell specific DOC2B overexpressing 
transgenic mouse (βDOC2B-dTg). My studies revealed that βDOC2B-dTg mice 
show enhanced whole-body glucose tolerance. After MLD-STZ treatment, 
βDOC2B-dTg mice displayed normal glucose tolerance. Furthermore, βDOC2B-
dTg mice show lower levels of β-cell apoptosis, corresponding with protected β-
cell mass, compared to control mice. In vitro, human and rodent β-cells 
transduced to overexpress human DOC2B also exhibit protection from pro-
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inflammatory cytokine-induced apoptosis, indicating that DOC2B protection 
occurs at the level of the β-cells, and the protective effect is not dependent upon 
inter-islet non β-cell communication nor is it due to a circulating factor in vivo.  
 
The role of DOC2B in β-cell survival mechanisms is still largely unexplored, 
however, in neurons, DOC2B has been implicated in proliferation and 
differentiation during early embryogenesis [105]. Yet, islet morphometry in mouse 
islets with increased or decreased DOC2B levels isolated from mice under 
standard conditions, unchallenged by diabetogenic stimuli, is reportedly 
unchanged from that of wild-type mice [24, 25, 33], which does not support the 
concept that DOC2B overexpression is acting via proliferative or differentiation 
mechanisms in the β-cell per se. My data rather point to the action of DOC2B 
overexpression in promoting β-cell survival and protecting β-cell mass against 
inflammatory stress, with the protection occurring at the level of the β-cell itself. 
4.1.4. DOC2B overexpression protects β-cells against cytokine 
induced apoptosis and reduces ER stress; The DOC2B peptide, 
C2AB, is sufficient to protect β-cells against Thapsigargin-induced 
ER stress. 
To further investigate the mechanism by which DOC2B confers anti-apoptotic 
effects, I show that cytokine-treated INS 832/13 β-cells overexpressing DOC2B 
have lower levels of cleaved caspase 3, CHOP, and Phospho-eIF2a. 
Furthermore, overexpression of DOC2B or the DOC2B peptide, C2AB, is able to 
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protect β-cells from Thapsigargin-induced ER stress in a calcium coordinating 
fashion that is dependent on C2AB’s calcium binding ability.  
 
DOC2B is a C2-domain containing protein, in the family of proteins including 
Munc13, synaptotagmins, Ferlins, Rabphilin 3A and RIM1/2 [176-178]. These 
proteins have in common two aspects: all are calcium regulated/calcium sensing, 
and all are implicated in vesicle trafficking/exocytosis. The role of DOC2B as a 
calcium sensor in β-cells has been reported [60] and the tandem C2 domain 
region of DOC2B, C2AB, has been shown to be sufficient to support membrane 
fusion in cell-free assays, and shows stronger liposome binding than either of the 
isolated C2A and C2B domains [106]. Indeed, our data show that C2AB can fully 
recapitulate the anti-apoptotic effects of full-length DOC2B in a calcium 
coordinating fashion. The calcium mutant form of C2AB has been previously 
reported to abolish DOC2B’s calcium binding capacity [179]. ER stress 
mechanisms are known to be calcium-dependent events, and thus we propose 
that DOC2B overexpression may lead to sequestration of calcium ions, resulting 
in reduced cleaved caspase 3, PARP, CHOP and P-eIF2a.  
4.1.5. The truncated C2AB domain confers the same GSIS enhancing 
properties as full length DOC2B 
Previous work has shown that overexpression of DOC2B enhances GSIS, 
although the mechanism underlying this beneficial action remains unresolved. 
DOC2B’s three primary domains, MID, C2A and C2B, each bind to a variety of 
proteins that might contribute to DOC2B function. My data revealed that the 
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tandem C2 domain region of DOC2B, C2AB, is the minimal region sufficient to 
fully recapitulate enhanced enhanced GSIS and SNARE complex formation, as 
seen with full length DOC2B. Neither of the individual C2 domains (C2A or C2B) 
are able to recapitulate the activating effect of full-length DOC2B. My data is 
consistent with prior work showing C2AB promoting SNARE protein assembly 
[180, 182]. C2AB may confer its SNARE complex-promoting effect by acting 
directly on the membrane [181]. Thus, C2AB may be a viable small molecule that 
can be used to promote and protect functional β-cell mass. 
 
4.2. FUTURE STUDIES  
4.2.1. Assess DOC2B abundance in platelets and islets from 
autoantibody positive, prediabetic T1D human subjects 
My data demonstrate reduced DOC2B levels in new-onset T1D human subjects. 
However, the current studies used relatively small sample sizes of pediatric 
subjects (N=14 controls and N=17 T1D) who already had clinical diabetes. 
Future investigations using subjects who are significantly at risk for T1D 
(presence of one or more autoantibodies), but not yet diagnosed, are necessary 
to validate the potential for DOC2B to be an early biomarker/indicator of pre-T1D 
in humans. My studies were also limited in that only the first clinic follow-up 
samples were obtained; further follow-up longitudinal evaluations of DOC2B 
changes for longer periods of time would be important to investigate any 
correlations between DOC2B levels and overall glycemic control. Future studies 
should also examine DOC2B levels in serum and plasma, both of which contain 
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abundant and detectable levels of DOC2B. This will permit studies of larger 
numbers of pre-/T1D subjects, as well as permit evaluation of stored samples 
from a variety of repositories. Yet, since platelets ‘sample’ proteins and mRNA 
from other cells, they may be the unique depot to detect changes in DOC2B 
levels corresponding to changes in functional islet mass. In order to 
accommodate a large cohort of samples, it would also be beneficial to create a 
DOC2B enzyme-linked immunosorbant assay (ELISA) designed for high 
sensitivity, high throughput assays using a well-validated, reliable human DOC2B 
antibody.  
 4.2.2. Assess DOC2B levels in circulating beta cell specific 
exosomes 
Notably, my studies revealed that islet infusion raised levels of platelet DOC2B in 
two T1D transplant recipients. This finding supports the concept that platelets 
and/or precursor megakaryocytes may be sampling DOC2B from the islets. 
Supporting the concept of islet-platelet ‘communication’, it has been shown that 
islet transplantation in T1D patients stabilizes platelet abnormalities [155]. Indeed 
β-cell specific exosomes have been identified carrying various miRNAs, mRNAs, 
and proteins to targeted peripheral cells [156]. It is possible that DOC2B mRNA 
or protein is shuttled to platelets via exosomes. Exosomes can be isolated from 
serum [157], using various isolation techniques. Future studies could then 
investigate changes in DOC2B levels in exosomes from blood samples of T1D 
subjects prior to and following islet transplantation. Exosomal release of DOC2B 
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can be further validated in vitro using human islets and rodent cell lines subjected 
to cytokine treatment to simulate T1D inflammation.  
 4.2.3. Beta cell specific DOC2B overexpressing transgenic NOD mice 
My data revealed DOC2B to have protective, anti-diabetic properties in rodents 
and in vitro. STZ is a commonly used reagent to model T1D in vivo, however, 
there are limitations to its use, as STZ is a chemical that causes β-cell 
destruction via alkylating mechanisms that damage β-cell DNA. While STZ is a 
useful chemical for pilot studies, it is not translatable to mechanisms involved in 
onset of T1D in humans. Future studies should aim to investigate effects of 
DOC2B overexpression in rodent models that are genetically susceptible to T1D. 
The NOD mouse is one of the most commonly used strains of spontaneously 
converting, T1D rodents. βDOC2B-dTg mice should be introgressed into the 
NOD strain to generate doxycycline-inducible, beta cell specific overexpressing 
NOD mice. Overexpression of DOC2B can be induced before and after 
conversion to T1D to further assess DOC2B’s potential to protect β-cell mass 
against onset of disease or to protect residual β-cell mass, respectively. Islets 
from the DOC2B overexpressing NOD mice can also be used in cytotoxic T 
lymphocyte (CTL) killing assay to quantify β-cell death and protection against 
lymphocytic destruction, as previously described [183]. 
 4.2.4. Transplantation of DOC2B/C2AB overexpressing human islets 
The C2AB region of DOC2B has been shown to promote SNARE assembly in 
neurons [181]. My studies demonstrated that the C2AB region of DOC2B is the 
minimal region required for enhanced GSIS and SNARE complex assembly in 
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the β-cell. Future studies should focus on the translatable potential to target 
C2AB as a peptide-based therapy to protect functional β-cell mass in a human 
islet transplantation model. An adenovirus should be generated to similarly 
overexpress C2AB, and perifusion analyses can be conducted to evaluate 
changes in first and second-phase insulin secretion. If C2AB similarly enhances 
insulin secretion in human islets, adenovirally transduced human islets 
overexpressing C2AB and/or full length DOC2B can be transplanted in diabetic 
mice. Our lab has recently used a minimal islet transplant paradigm to test the 
ability of STX4 upregulation in transplanted islets to reverse diabetes in STZ-
induced diabetic mice [9]. Similarly, the minimal islet transplant model should be 
used in recipient NSG (NOD scid gamma immunodeficient) mice prior to 
treatment with high dose STZ (180 mg/kg body weight), as previously described 
[9] and blood glucose measurements obtained to assess glucose homeostasis 
and the ability of C2AB and/or DOC2B to protect islet grafts from diabetic insults.  
4.2.5. Investigate DOC2B’s Ca2+ handling and protection from 
apoptosis. 
DOC2B’s calcium sensing properties have been extensively studied in neurons 
[106, 176, 179], and to a lesser extent in the β-cell [60]. Furthermore, my studies 
are the first to establish that DOC2B can protect β-cells from diabetic insults, 
specifically via calcium coordination and reduction of ER stress. I showed that a 
mutant form of C2AB (calcium ligand binding mutations at 4 residues) was 
unable to protect against thapsigargin-induced ER stress and apoptosis. This 
should be further investigated. Isolthermal titration calorimetry (ITC) should be 
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used to validate the ability of DOC2B, C2AB, and the calcium mutant (CaMut) to 
bind Ca2+ in the β-cell, using methods as previously described [179]. Intracellular 
calcium levels should be quantified using a reagent such as Fura-2 AM (using 
techniques as described [179]) in DOC2B or C2AB overexpressing β-cells that 
are subjected to cytokine or thapsigargin treatment in order to further prove that 
DOC2B/C2AB is sequestering Ca2+ stores, leading to protection against ER 
stress. RNA sequencing should be performed on cytokine treated-human islets 
overexpressing DOC2B or C2AB in order to identify further potential 
transcriptional “hits” involved in DOC2B’s anti-apoptotic mediating effects. 
Immunoprecipitation experiments using DOC2B overexpressing EndoC-βH1 
subjected to cytokine treatment should also be performed followed by mass 
spectrometry to investigate the presence of novel DOC2B interacting binding 
partners involved in its anti-apoptotic effects. 
 4.2.6. Investigate DOC2B overexpression in context of T2D 
DOC2B transcript levels are reportedly reduced in islets of pre-T2D mice. These 
data suggest that DOC2B deficiency may also underlie susceptibility to T2D-
related islet damage. Given that DOC2B overexpression protected β-cells 
against T1D-related insults, a high fat diet paradigm (as previously described 
[151] should be used on βDOC2B-dTg mice to assess DOC2B’s protection of β-
cell mass under glucolipotoxic and insulin resistant conditions. Human islets 
overexpressing DOC2B should also be treated with glucolipotoxic conditions to 
investigate the translatable nature of DOC2B’s proposed protective/anti-apoptotic 
effects. 
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4.2.7. How to target overexpression of exocytosis factors  
Potential delivery options for increasing cellular levels of exocytosis proteins, 
such as DOC2B, are likely to vary in an isoform-type and context-specific manner. 
Based on current therapeutic options being explored in neurons, a recent study 
has utilized a truncated form of SNAP25 conjugated to human Hph-1, a protein 
transduction domain which allows penetration of various macromolecules into the 
cytoplasm and nucleus both in vitro and in vivo through local or systemic 
administrations [184]. This approach may be useful for treating 
neurodegenerative disorders, as Hph-1 conjugated proteins can cross the blood 
brain barrier. Additional delivery options involve gene therapy approaches using 
adeno-associated virus vectors (AAV), a delivery system currently being 
investigated in clinical trials for several diseases [185-187]. AAV vectors have 
recently been implicated in treating neurodegenerative disorders, as 
characterization of several novel AAV serotypes has shown that a single 
intravenous injection in adult mice leads to transduction of neural cells 
throughout the entire central nervous system [188]. Recent characterization of 
several novel AAV serotypes has revealed ideal serotypes for targeting skeletal 
muscle and pancreas [186, 189-191], and could potentially be utilized for gene 
therapy to target exocytosis proteins in treating pre-/T2D. Other options include 
enhancing human pancreatic islets with DOC2B slated for subsequent clinical 
transplantation. This would be most applicable to individuals with T1D, although 
clinical trials using transplantation procedures in T2D are currently being pursued 
[192, 193]. Notably appealing for clinically effective druggable targets is that 
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achieving high levels of overexpression of DOC2B would not be necessary, and 
that DOC2B does not trigger fasting hypoglycemic episodes, culminating in a 
safe and effective means to treat T1D.  
 
4.3. CONCLUSIONS 
 
Overall, my studies revealed that DOC2B protein abundance is reduced in 
platelets and pancreatic islets during development of T1D in rodents, and in 
platelets of new-onset T1D pediatric subjects and islets of T1D cadaveric human 
donors. Remarkably, transplantation of islets correlated with normalized platelet 
levels of DOC2B in T1D human subjects, as abundance of DOC2B was elevated 
to the same level seen in non-diabetic individuals. DOC2B deficiency enhances 
susceptibility to T1D damage in mice, and overexpression of DOC2B protects β-
cell mass against T1D insults in an anti-apoptotic and anti-ER stress manner. 
Furthermore, the C2AB region of DOC2B is sufficient to resist thapsigargin-
induced ER stress, and requires intact calcium binding residues therein. C2AB is 
also the minimal domain required for enhanced GSIS, as seen with full-length 
DOC2B. In sum, these studies are significant because they are the first to 
establish an association between T1D and levels of DOC2B in blood-borne 
platelets and pancreatic islets in rodents and humans, and this can be exploited 
in further biomarkers studies for clinical applications. Furthermore, these studies 
show a novel, anti-apoptotic role for DOC2B in the β-cell, which is the initial step 
in establishing DOC2B as a potential therapeutic target for 
prevention/management of T1D. 
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